Front. Nutr. Frontiers in Nutrition Front. Nutr. 2296-861X Frontiers Media S.A. 10.3389/fnut.2026.1761992 Review Nutrition and the gut microbiome: a symbiotic dialogue influencing health and disease Ray Sayantanee Investigation Writing – original draft Shankaran Prakash * Conceptualization Methodology Supervision Writing – original draft Writing – review & editing Virology and Ayurgenomics Laboratory, SASTRA-IKS Center for Ayurgenomics, School of Chemical and Biotechnology, SASTRA Deemed to Be University, Thanjavur, India Correspondence: Prakash Shankaran, prakash@scbt.sastra.edu 12 02 2026 2026 13 1761992 06 12 2025 19 01 2026 23 01 2026 Copyright © 2026 Ray and Shankaran. 2026 Ray and Shankaran https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

The gut microbiome, a complex consortium of trillions of microorganisms, significantly influences human health through its metabolic activities, immune modulation, and interaction with the nervous system. Diet plays a significant role in shaping the gut microbiome, with plant-based diets promoting the colonization of beneficial bacteria and fiber fermentation, whereas meat-based diet may encourage harmful microbial shifts associated with systemic inflammation. Gut bacteria produce short-chain fatty acids (SCFAs) from dietary fibers and those are crucial for energy metabolism, intestinal integrity, and immune modulation. Certain neurotransmitters like GABA and serotonin produced by gut bacteria, play a vital role in the gut-brain axis. Dysbiosis in the gut microbiota have been linked to various psychiatric and neurological disorders like anxiety, depression, bipolar disorder, Schizophrenia, Alzheimer’s and Parkinson’s. Beyond neurological implications, the gut microbiota also linked to metabolic and cardiovascular diseases, including obesity, hypertension, and coronary artery disease, as well as colorectal cancer. Imbalances in bacterial ratios, such as Firmicutes to Bacteroidetes, can impact metabolism and inflammation. This review (i) elucidates the complex interplay between nutrition and the gut microbiome, emphasizing its implications for human health and disease; (ii) critically examines the methodological and analytical limitations inherent in current metagenomic studies; and (iii) proposes an integrated, multi-layered, systems-level framework for developing predictive models of host–microbe interactions and their pathological significance.

 food metabolome metagenome microbiome nutrition The author(s) declared that financial support was received for this work and/or its publication. We are grateful to the Indian Knowledge System (IKS) Division, Ministry of Education (MoE), Government of India, for the financial support provided for this research work and fellowship for SR through project [F.2-23/AICTE/IKS-BGS1/ResearchProject/2022-23/24]. section-at-acceptance Nutrition and Microbes Introduction

The human gastrointestinal tract harbors an exceptionally dense population of microbial cells, collectively referred to as the gut microbiome (1). This complex ecosystem plays a crucial role in maintaining health and facilitating various physiological processes. The gastrointestinal (GI) tract serves as one of the largest interfaces-spanning approximately 250–400 m2, between the host, external environmental factors, and endogenous antigens. Throughout an average lifespan, the GI tract processes more than 60 tons of food and is exposed to a substantial influx of environmental microbes that can challenge the integrity of the gut barrier (2). The term “gut microbiota” encompasses the diverse community of bacteria, viruses, fungi, and algae residing in the GI tract. Over millennia, these microorganisms have co-evolved with their hosts to establish a sophisticated and mutually beneficial symbiotic relationship (3, 4). Recent studies estimate that microbial cells in the human body exist in a roughly 1:1 ratio with human cells. Remarkably, the gut microbiome contains approximately 3.3 million non-redundant microbial genes which is 150 times greater than the 21,000 genes encoded by the human genome (5). In adults, the gut microbiome comprises over 1,000 distinct species and more than 7,000 bacterial strains (6). Notably, while humans share 99.9% genetic similarity with one another, their gut microbiomes can differ by as much as 80%–90%, highlighting its dynamic and individualized nature (7, 8). Diet plays a crucial role in maintaining the composition, function and diversity of the gut microbiome; eventually, gut microbiome derived serum metabolites show beneficial effects on health; while some may serve as disease biomarkers. Understanding the interplay between diet, gut microbiome and serum metabolome and its impact on health and disease will be discussed further.

 Dietary source influencing gut microbiome Food

Dietary habits have a profound impact on our gut ecosystem. Diet contributes macronutrients (carbohydrate, protein, fat), micronutrients (minerals and vitamins) and phytochemicals. Carbohydrate, fiber, protein and fat show significant influence on regulation of prevalence of different microbial species (9). Figure 1 showcases how gut microbiota derived metabolites affect health and disease.

Gut microbiota derived metabolites and their function in health and disease.

A comparison chart of four diets: Plant-Based, Mediterranean, Meat-Based, and Processed. Each diet lists associated foods and effects on gut bacteria. Plant-Based and Mediterranean diets increase beneficial bacteria like Bifidobacterium, leading to short-chain fatty acids that maintain health. Meat-Based diet decreases these bacteria, with an increase in compounds like trimethylamine linked to cardiovascular disease. Processed diet increases harmful bacteria like Firmicutes, associated with inflammatory responses. Benefits include improved inflammation and intestinal integrity, while risks include cardiovascular and inflammatory diseases. Carbohydrates

Carbohydrates can be broadly categorized into two types: digestible and indigestible. The gut microbiota ferments insoluble dietary fibers and indigestible polysaccharides into bioactive metabolites known as short-chain fatty acids (SCFAs). Among these SCFAs, acetate (C2), propionate (C3), and butyrate (C4) are the most abundant, typically found in ratios of approximately 3:1:1 (10). These linear monocarboxylic acids with fewer than six carbon atoms play critical roles in energy metabolism, maintaining intestinal barrier integrity, modulating immune cell development, and exhibiting anti-inflammatory properties (11–13). SCFA production involves multiple biochemical pathways; acetogenic bacteria utilize the Wood–Ljungdahl pathway to convert CO2 into acetyl-CoA directly, which can further be converted to acetate; while glycolysis converts glucose to pyruvate which can be further processed to produce acetate (14). Butyrate synthesis occurs via the transformation of aceto acetyl-CoA into butyryl-CoA and subsequently into butyrate. Acetate is predominantly synthesized by species such as Acetobacter and Gluconobacter (12, 14, 15). Key human gut bacteria that produce propionate include members of the genus Bacteroides (B. fragilis, B. thetaiotaomicron, B. eggerthii), while Veillonella parvula utilizes succinate as a substrate for propionate production. Additionally, Coprococcus and Ruminococcus species can produce propionate through acrylate and propanediol pathways respectively (16, 17). Within the Firmicutes phylum, bacterial genera such as Ruminococcaceae, Lachnospiraceae, Erysipelotrichaceae, and Clostridiaceae are prominent producers of butyrate. Specific species like Clostridium butyricum and Butyrivibrio fibrisolvens are also key contributors for butyrate (18, 19).

The small intestine uses enzymes to break down digestible carbohydrates, such as starch, fructose, sucrose, and lactose which are metabolized to release glucose into the circulation and trigger an insulin response. Date is a rich source of dietary fiber and polyphenols. Investigation on gut bacterial changes induced by the whole date fruit extract (digested date extract; DDE) and its polyphenol-rich extract (date polyphenol extract; DPE) revealed that both the DDE and DPE extracts enhance the gut health by increasing the beneficial bacterial growth and inhibiting the colon cancer cells. Though both extracts were found to be beneficial the DDE significantly increased both Bifidobacteria and Bacteroides levels when compared to DPE. In addition, bacterial metabolism of whole date extract (DDE) led to the production of SCFA, flavonoid aglycones (myricetin, luteolin, quercetin and apigenin) and the anthocyanidin petunidin (20). Hydrolyzed lactose has been shown to modulate the composition of gut microbiota by inducing the proliferation of Lactobacillus and Bifidobacteria while simultaneously suppressing Bacteroides and Clostridia population in infants with milk-allergy. Furthermore, metabolomic analysis elucidated that lactose supplementation significantly elevated fecal concentrations of beneficial short-chain fatty acids (SCFAs), especially acetic acid and butyric acid (21). Diets high in non-digestible carbohydrates, such as whole grains and wheat bran, have been linked to increased levels of Bifidobacteria and Lactobacilli (22, 23). The population of Ruminococcus, E. rectale, and Roseburia also seems to be increased by other non-digestible carbohydrates including resistant starch and whole grain barley (24–26). A cross-sectional study involving 344 patients with advanced colorectal adenomas found that, compared to healthy controls, these patients had higher levels of Enterococcus and Streptococcus but lower levels of Roseburia and Eubacterium (27). Additionally, low amount of non-digestible carbohydrates in the diet predominantly reduce the levels of Roseburia spp. and E. rectale subgroup of cluster XIVa from the Firmicutes phylum and also the level of Bifidobacterium from the Actinobacteria phylum (28).

 Proteins

A substantial body of research reveals a positive correlation between total microbial diversity and protein intake. Consuming whey and pea protein extract has been demonstrated to raise the population of gut-commensal Bifidobacterium and Lactobacillus, while whey protein also reduces pathogenic Bacteroides fragilis and Clostridium perfringens (29–31). Additionally, pea protein has been noted to elevate intestinal SCFA levels, which are thought to have anti-inflammatory properties and are crucial for maintaining the mucosal barrier (32). Conversely, it has been observed that the consumption of animal-based protein increases the counts of bile-tolerant anaerobes like Bacteroides, Alistipes and Bilophila (33–35). Increased Bacteroides population is associated with higher intakes of animal protein and different types of amino acids (36). A study on Italian youth found that their gut microbiota was more abundant in Bacteroides and Alistipes when they consumed higher amounts of animal protein (37). Furthermore, individuals following a high-protein, low-carb diet have lower levels of butyrate in their stools and fewer populations of Eubacterium rectale and Roseburia in their gut microbiota (38). Ingesting red meat has been linked to the promotion of numerous microbial genera that have also been linked to elevated levels of trimethylamine-N-oxide (TMAO), a proatherogenic substance that raises the risk of cardiovascular disease (39). Tryptophan is an essential amino acid, often found in most protein rich foods, including both animal and plant protein sources like chicken, eggs, fish, milk, cheese, peanuts, seeds, soy beans (40). Tryptophan is a precursor of serotonin (5-HT) and majority of body’s serotonin is produced by gut bacteria. Lactobacillus and Streptococcus can produce serotonin directly using tryptophan synthetase enzyme. Ruminococcus gnavus and Clostridium sporogenes can convert tryptophan into tryptamine via the enzyme tryptophan decarboxylase. Gut colonizer Clostridia sp. can signal the enterochromaffin cells of gut to increase serotonin production from this tryptamine (41). On the other hand, Lactobacillus, Bifidobacterium and Bacteroides produce GABA from L-glutamate through the glutamate decarboxylase pathway (42).

 Fat

Diets rich in saturated and trans fats are likely to elevate blood total and LDL cholesterol levels, thereby increasing the risk of cardiovascular disease (43, 44). Conversely, beneficial lipids such as mono and polyunsaturated fats play a major role in reducing the chance of developing chronic illnesses. Typical western diets are predisposed to numerous health issues since they are low in mono and polyunsaturated fats and high in trans and saturated fats (45–47). In a comparative study, the scientists observed that a low-fat diet increased the amount of Bifidobacterium in the feces while simultaneously lowering total cholesterol and fasting glucose levels. Conversely, a diet high in saturated fat raised the presence of Faecalibacterium prausnitzii (48). A high-fat diet has been demonstrated to lower the concentration of Bacteroides species from the Bacteroidetes phylum, Eubacterium rectale, and Blautia cocoides from the Firmicutes phylum (49).

 Probiotics

Fermented foods like yogurt and cultured milk products, are a source of edible microorganisms that may help to maintain intestinal health and even cure or prevent inflammatory bowel disease (IBD) (50). They are believed to achieve this through their immune modulatory properties such as activation of anti-inflammatory cytokines such as IL-10 and IL-12 (51), and reducing pro-inflammatory molecules such as IL-8 and nitric oxide (NO) levels (52) as well as their impact on the current gut flora. Foods enriched with beneficial bacteria are known as probiotics because of their health-promoting characteristics (53–56). A randomized, placebo-controlled trial involving sixty overweight but otherwise healthy adults demonstrated significant increases in the concentrations of total aerobes, anaerobes, Lactobacillus, Bifidobacteria, and Streptococcus among participants who received probiotics containing three strains of Bifidobacteria, four strains of Lactobacilli, and one strain of Streptococcus, compared to those receiving a placebo. Additionally, these participants exhibited lower levels of triglycerides, total cholesterol, LDL cholesterol, VLDL cholesterol, and high-sensitivity C-reactive protein (hsCRP), along with reduced counts of total coliforms and Escherichia coli. Furthermore, probiotic treatment was associated with improved insulin sensitivity and increased HDL cholesterol levels. Notably, individuals with baseline low HDL, elevated hsCRP, and greater insulin resistance initially had fewer total Lactobacilli and Bifidobacteria but more Escherichia coli and Bacteroides (57).

 Polyphenols

The antioxidant properties of dietary polyphenols, including phenolic acids, anthocyanins, flavanols, flavones, and proanthocyanidins, are being intensively researched. Foods rich in polyphenols include wine, tea, cocoa products, fruits, seeds, and vegetables (58). Ortuno et al. investigated the effect of moderate intake of red wine polyphenols on selected gut microbial groups. Daily intake of red wine for 4 weeks significantly boosted Enterococcus, Prevotella, Bacteroides, Bifidobacterium, Eggerthella lenta, Blautia coccoides and Eubacterium rectale populations alongside reduction in systolic/diastolic blood pressure, triglycerides, total HDL (high density cholesterol) and C-reactive protein. Notably, shifts in cholesterol and CRP correlated with Bifidobacteria abundance (59). However, these findings from red wine polyphenols must be interpreted cautiously, as alcohol consumption-even moderate carries substantial risks including cancer, as per the 2025 U.S. Surgeon General’s Advisory, where benefits remain uncertain and may not outweigh harms. In a study examining their antibacterial effects, enteropathogens such as Staphylococcus aureus and Salmonella typhimurium were found to be highly sensitive to polyphenols derived from fruits (60). A decrease in pathogenic Clostridium species has been observed with the ingestion of polyphenols from fruits (61), cocoa (62). Study on tea phenolics repressed certain pathogenic bacteria like Clostridium perfringens, Clostridium difficile and Bacteroides spp. while commensal anaerobe Bifidobacterium spp. and probiotic Lactobacillus sp. were less affected (63).

 Dietary habits Plant-based diets

High fiber intake supports the growth of beneficial microbes and the production of SCFAs having various health benefits. Conversely, diets high in animal products are often associated with increased levels of certain pathogenic bacteria (64). Vegan and vegetarian diet rich in fruits and vegetables are commonly associated with a gut microbiome signature enriched in bacteria like Lachnospiraceae, Butyricicoccus and Roseburia hominis which specialize in breaking down SCFAs (65–68). A study investigated the Indian Thali, a traditional platter (including dal, curd, spices, sambhar and rasam) provides various kinds of phytochemicals (curcumin, flavonoids, tannins, isoflavone, anthocyanin, glucosinolates, carotenoids), is beneficial for gut microbiota (69). Anthocyanin-a subgroup of flavonoids (sub class of polyphenols) is known for its antioxidant and anti-inflammatory properties, which help mitigate oxidative stress. It reduces the accumulation of reactive oxygen species (ROS) and downregulates the expression of Interleukin 6 (IL-6) gene which upregulates a transcription factor known as STAT3. Since STAT3 drives cell proliferation and anti-apoptotic signaling, its modulation is critical; uncontrolled STAT3 activity may contribute to the pathogenesis of detrimental health outcomes such as cancer and Inflammatory bowel disease (IBD) (70). Catechin and epicatechin have anti-inflammatory and antioxidant properties. Catechins mostly found in green tea may also be useful in preventing angiogenesis and metastasis (71).

 Mediterranean diet

The Mediterranean diet is characterized by a favorable fatty acid profile, high in polyunsaturated and monounsaturated fatty acids, high intake of fiber and other low-glycemic carbohydrates, and a relatively higher intake of vegetable protein compared to animal protein (72). Significant correlations were found between the degree of Mediterranean diet adherence and elevated fecal SCFA, Prevotella, and other Firmicute levels. Conversely, there was a correlation between poor adherence to the Mediterranean diet and greater urine trimethylamine oxide, a marker of enhanced cardiovascular risk (39). Foods that make up the classic Mediterranean diet have also been demonstrated in several other trials to improve inflammation, lipid profiles, and obesity, potentially mediated by decreases in Clostridium and increases in Lactobacillus, Bifidobacterium, and Prevotella (73–75).

 Meat-based diets

Meat based diets have been shown to decrease the beneficial commensal bacteria like Bifidobacterium and Eubacterium spp. The Western diet regarded as high calorie fat diet contain heterocyclic amines (HCA), polycyclic aromatic hydrocarbons (PAH), and emulsifiers may lead to carcinogenesis. These compounds can damage the DNA of colonocytes and increase the risk of colorectal cancer (76). Higher meat intake is associated with increased levels of Firmicutes, Bacteroides, Proteobacteria, Actinobacteria (77). Bilophila wadsworthia, thrives on fats and bile, leads to a reduction in gut microbial diversity and an increase in harmful metabolites like TMAO, which is linked to inflammation and cardiovascular disease (78).

 Processed food

Processed food including burgers, pizza, carbonated beverages negatively impact gut microbiome by reducing microbial diversity and decreasing beneficial bacteria. Akkermansia municiphila, which is known to aid in weight management and improve insulin sensitivity, has been found to be less prevalent in individuals consuming diets rich in processed foods (79). One Spanish population study showed processed food consumers have decreased levels of Lachnospira and Roseburia which are commonly known as SCFAs producers; potentially harmful bacteria were elevated compared to those who consumed a diet with low processed food. These bacteria included Blautia, Carnobacteriaceae, Bacteroidetes which have been associated with metabolic disorders (80). Processed food contains synthetic additives, low fiber and emulsifiers including carboxymethylcellulose, polysorbate 80, carrageenan has been shown to change the microbiota, promoting pro-inflammatory microbial environment which may influence to develop obesity, Type 2 diabetes. These emulsifiers reduce Faecalibacterium prausnitzii which have anti-inflammatory qualities and negatively impact on the intestinal mucus layer, increasing permeability known as “leaky gut” and bacterial translocation into the bloodstream which may cause systemic inflammation (81, 82).

 Gut microbiota associated diseases

The gut microbiome forms complex and dynamic interactions with most of the organs of the body, establishing multiple physiological axes such as the gut-brain, gut-lung, gut-liver, gut-cardiac axis. These interconnected pathways underline the critical role of gut microbiota in maintaining systemic health and contribute to the pathogenesis of diverse diseases through disrupted microbial balance and immune modulation (Figure 2).

Gut-organs axis: gut-microbiome associated disease.

Diagram illustrating the gut-brain, gut-liver, gut-lung, gut-pancreas, gut-cardiac, gut-cancer, gut-immune axes and their health connections. Issues include stress, liver disease, respiratory diseases, diabetes, cardiovascular conditions, cancer, and autoimmune disorders. Central image of intestines with arrows pointing to each axis and its related diseases. Gut-immune axis

The gut microbiota plays a critical role in the development and regulation of the host immune system through metabolites such as SCFAs contributes to host immune regulation via multiple mechanisms-including G-protein couples receptor (GPCR) signaling (e.g., GPR43/41), histone deacetylase (HDAC) inhibition and cytokine modulation-one of which involves the context dependent balance of Th17 and regulatory T (Treg) cells to support immune homeostasis in physiological states (83, 84) and diseases like rheumatoid arthritis (RA) or autoimmune hepatitis (AIH) (85, 86). The differentiation of the four primary subtypes of CD4+ T cells–Th1, Th2, Th17, and Tregs–is significantly influenced by the gut microbiome (87). Tregs, in particular, are crucial in mitigating inflammatory responses and preventing autoimmune diseases by suppressing other cell types (88). Clostridium species can promote Treg production (89), while B. fragilis can activate Tregs to inhibit pro-inflammatory Th17 responses (90). Moreover, colonic Tregs possess a unique repertoire of T cell receptors that recognize bacterial components in the colon (91). Additionally, the gut microbiota is essential for the existence and functionality of intestinal CD8+ T cells, as well as their capacity to modulate other immune cell populations, including natural killer cells, plasmacytoid dendritic cells, and marginal zone B cells (92–94).

Rheumatoid arthritis (RA) is a chronic autoimmune, inflammatory, and systemic disease characterized by the progressive degeneration of bone and cartilage, ultimately resulting in functional impairment. The inflammatory response in RA is mediated by CD4+ T cells, particularly Th1 and Th17 lymphocytes, as well as an imbalance between Th17 cells and Tregs. This dysregulation has been closely linked to the pathogenesis of RA (95). Taxonomic analyses have revealed that RA patients exhibit reduced levels of Actinobacteria compared to healthy controls. Experimental approach shows Lactobacillus species–such as L. salivarius, L. iners, and L. ruminis–predominate in the gut microbiota of RA patients compared to healthy individuals; (96) meanwhile machine learning approaches, such as the random forest method, specific microbial taxa like Faecalibacterium, Collinsella, and Eggerthella have been associated with RA. Notably, increased levels of Collinsella correlate with elevated production of alpha-aminoadipic acid, asparagine, and IL-17A which in turn influences gut permeability and exacerbates RA severity (97). Interestingly two different species of bacteria from similar genus showing contrasting effects; for example, Prevotella histicola, has been shown to inhibit RA development; whereas, Prevotella copri is more abundant in some patients with early-stage RA and has been implicated in disease progression (98). Patients with Crohn’s disease-an autoimmune disorder of digestive tract showed a reduction in Faecalibacterium and Roseburia spp. but an increase in Escherichia, Fusobacterium and Mycobacterium spp. (99). It was discovered that the lactate and butyrate-producing bacteria in the control group were responsible for the production of mucin, which is essential for maintaining gut integrity. Conversely, non-butyrate-producing lactate-utilizing bacteria, which are implicated in Type 1 diabetes and β-cell autoimmunity suppressed the production of mucin (100).

 Gut-brain axis

The acquisition of gut microbiota begins at birth, and by the age of 12–36 months, infant microbiota profiles resemble those of adults (101–103). This critical period, spanning from birth to 36 months, is marked by significant neurodevelopmental milestones and immune system maturation (104–106). During this time, the gut microbiota plays an active role in various neurodevelopmental processes, including the formation of the blood-brain barrier (BBB) (107), neurogenesis (108), microglia maturation (109), and myelination (110, 111). These mechanisms play a crucial role in shaping cognitive functions and behavioral patterns. The gut microbiota produces a range of metabolites that serve as signaling molecules capable of directly stimulating the vagus nerve or crossing the intestinal barrier into the circulatory system and potentially the blood-brain barrier, thereby influencing neurological functions (112, 113). Commensal bacteria, such as Lactobacillus, synthesize neurotransmitters like gamma-amino butyric acid (GABA), dopamine, noradrenaline, and histamine, which are essential for neurophysiological and neurodevelopmental processes (114). The gut microbiome is interconnected with the central nervous system through several pathways, including the enteric and autonomic nervous systems, the hypothalamic-pituitary-adrenal (HPA) axis, and hormone signaling networks (115, 116). One such pathway involves tryptophan metabolism, which yields serotonin as a final product, primarily produced by gut flora such as Streptococcus spp., Enterococcus spp., Escherichia spp., and Klebsiella pneumoniae. The gut-brain axis, particularly its connection to anxiety and stress disorders, has been linked to the HPA axis (40, 117).

Psychiatric disorder

Mental illness is a hidden epidemic that has been progressively spreading throughout the world. Gut microbiota dysbiosis is linked to higher risk of mental health condition and psychiatric diseases (118, 119). In a study involving 40 patients diagnosed with generalized anxiety disorder (GAD) exhibit altered gut microbiota compositions compared to 36 healthy individuals, characterized by reduced levels of Firmicutes–which are key producers of SCFAs–and increased levels of Fusobacteria and Bacteroidetes (120). Another study demonstrates patients with depression had lower levels of Dialister and Coprococcus spp. (121). The data demonstrated that major depressive disorder patients had reduced levels of Bacteroidetes in contrast increased abundances of Prevotella, Klebsiella, Streptococcus, and Clostridium XI (122). In bipolar disorder (BD), gut microbiota diversity is notably diminished, with a predominance of Clostridiaceae and Collinsella (123). Bipolar illness patients had much lower levels of Faecalibacterium, according to another cross-sectional investigation (124), alongside reduced abundances of Ruminococcaceae. One study demonstrate higher levels of Actinobacteria and Coriobacteria have been observed while (125) interestingly no significant differences were found in the counts of Bifidobacterium, Lactobacillus bacteria between the two cohorts of 39 people with bipolar disorder and 58 healthy persons (126). In children with autism spectrum disorder (ASD), gut microbiota analyses have shown increased abundances of Actinobacteria, Proteobacteria, and Bacilli (127). From an Egyptian study it has been revealed that children with ASD had higher abundance of Clostridium paraputrificum, Clostridium bolteae, and Clostridium perfringens compared to the neurotypical children. Notably, children with ASD harbored Clostridium diffiicile and Clostridium clostridioforme, while neurotypical children exclusively carried Clostridium tertium; thus, species level identification revealed clear difference between the two cohorts (128). Apart from this, there is a substantial correlation between the ratio of Firmicutes to Bacteroidetes in the gut microbiota and hypertension (129).

 Neurodegenerative disorder

Gut microbiota dysbiosis cause high permeability of the intestine and BBB through the gut-brain axis by increasing LPS, T helper cells, pro inflammatory cytokines; which results in misfolded protein accumulation, neuronal demyelination and axon damage. These can lead to neurodegenerative disorders like multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), Parkinson’s disease (PD) (130).

Akkermansia muciniphila, Hungatella hathewayi, Ruthenibacterium lactatiformans and Eisenbergiella tayi have been found in higher proportion in the patients diagnosed with MS while beneficial microbes that produce SCFAs like Faecalibacterium prausnitzii and Blautia sp. have been found in lower abundance (131, 132). Altered microbial structure of ALS patients has been reported, lower abundance of Firmicutes and Megamonas at phylum and genus level respectively while higher abundance of Bacteroides at the phylum level (133). Dorea formicigenerans, Oscillibacter sp., Faecalibacterium prausnitzii, Coprococcus catus were mostly associated with preclinical AD status (134). In another study 16s rRNA amplicon sequencing revealed that AD patients had a decrease in Faecalibacterium and increase in Bifidobacterium compared to controls (135). According to reports, the relative abundance of Verrucomicrobiaceae and Akkermansia is higher in PD patients while Prevotellaceae is lower (136). A meta-analysis of 15 case-control studies identified that Ruminococcaceae, Bifidobacteriaceae, Christensenellaceae and Verrucomicrobiaceae were enriched in PD patients. In contrast Prevotellaceae, Lachnospiraceae and Faecalibacterium were significantly reduced in PD patients compared to healthy controls (137). Patients with schizophrenia exhibited higher abundances of Veillonella accompanied by reduced level of Ruminococcus and Roseburia (138). Another study found increased prevalence of Lachnospiraceae in schizophrenia patients along with a unique microbiome composition (139). Furthermore, various facultative anaerobes, such as Lactobacillus fermentum and Enterococcus faecium, which are uncommon in healthy individuals, were identified in schizophrenic patients (140). A separate cross-sectional study revealed that schizophrenia patients had higher levels of Proteobacteria, while exhibiting reduced abundances of Faecalibacterium and Lachnospiraceae (141).

 Gut-pancreas axis

A subset of gut bacteria, collectively referred to as the obesogenic gut microbiota, including certain species of Firmicutes, Bacteroidetes, Rhizobium, Lactococcus, and Clostridium, are positively associated with obesity development (142). Research has demonstrated that transitioning from a high-fat, low-fiber diet to a low-fat, fiber-rich diet can induce profound changes in gut microbiota composition within a mere 24 h. An elevated intake of dietary fat reduces the population of Lactobacillus organisms while increasing Gram-negative bacteria (143, 144). Especially, an elevated level of Lactobacillus reuteri and lower levels of Lactobacillus casei and Lactobacillus plantarum were correlated to obesity (145–148). In obese persons energy storage level is high due to the enhanced hydrogen transfer between microbial taxa. This is accompanied by a concurrent increase in hydrogen-producing Prevotella and methanogenic archaea that utilize nitrogen (149, 150). The underlying mechanism involves methanogenic archaea converting hydrogen into methane, thereby allowing for greater energy extraction from the same daily caloric intake (151–154). Patients with Type 2 diabetes mellitus (T2DM) have been reported with gut microbiota dysbiosis. Opportunistic pathogens including Clostridium hathewayi, Clostridium symbiosum, Clostridium ramosum, Bacteroides caccae, Eggerthella lenta and E. coli increased in T2DM patients while healthy controls showed higher abundance of butyrate producing bacteria (155, 156). Another study showed Eubacterium rectale, Faecali prausnitzii, Roseburia intestinalis, Roseburia inulinivorans are particularly depleted in T2DM patients (157–159). Akkermansia muciniphila and Faecali prausnitzii protect against the pathogenesis of T2DM by maintaining the integrity of mucin layer and reducing inflammation (160, 161).

 Gut-liver axis

A targeted metagenomics and metabolomics study involving non-alcoholic fatty liver patients from Italy showed a greater level of 2-butanone and 1-pentanone and lower levels of Oscillospira compared to healthy controls (162). In hepatitis B virus-related liver cirrhosis (HBV-LC) Bacteroides, Prevotella, Escherichia, Parabacteroides, Veillonella, and Klebsiella were enriched while Bifidobacterium, Faecalibacterium, Roseburia, Ruminococcus, Blautia, Eubacterium were reduced in genus level. Additionally, species level identification showed enrichment of Prevotella copri, Bacteroides vulgatus, E. coli, Fusobacterium nucleatum and Veillonella spp. in HBV-LC (163).

 Gut-cardiac axis

The composition of gut microbiota also differs significantly in patients with coronary artery disease (CAD), with Bacteroidetes being less prevalent and Firmicutes more abundant. One metabolite that contributes substantially to atherosclerosis and can be used to estimate cardiovascular risk is trimethylamine-N-oxide (TMAO) (164). Severe coronary atherosclerosis is known to be associated with elevated Enterobacteriaceae (165). Similarly, CAD is associated with an increased abundance of Streptococcus and Enterobacteriaceae (166). Heart failure patients showed increase in pathogenic bacteria in their gut microbiome; Campylobacter, Salmonella, Shigella, Candida species (167).

 Gut-cancer axis

Imbalance in gut microbiome can lead to chronic inflammation and this sustained inflammatory response can damage DNA in cells, which may initiate tumor development. In patients with prostate cancer, elevated levels of Bacteroides massiliensis and significantly lower levels of Eubacterium rectale and Faecalibacterium prausnitzii have been detected, indicating these particular microbes may play a role in the etiology of prostate cancer (168). The development of colorectal cancer is associated with gut microbiota, and key contributors in this process have been identified as Fusobacterium nucleatum, Bacteroides fragilis and Peptostreptococcus anaerobius (169). Research suggests that gut bacteria, particularly F. nucleatum and Clostridium colicanis, are suggestive indicators of the carcinogenesis of stomach cancer (170). F. nucleatum can promote cellular proliferation and inhibit the host’s immunological response. Notably, a diet rich in dietary fiber and whole grains is associated with a decreased incidence of F. nucleatum positive cancer, suggesting that the gut microbiota may play a key mediating role in the interactions between food and colorectal cancer (171).

 Gastrointestinal disorder

A healthy diverse microbiome helps maintain a strong intestinal barrier while dysbiosis in gut microbiome leads to “leaky gut,” allowing pathogens and food antigens to cross the barrier and trigger immune response which further leads to inflammation. In inflammatory bowel disease (IBD) patients, significant reductions in Firmicutes and Proteobacteria have been noted, including a decrease in the Clostridium leptum group, particularly F. prausnitzii (172). A study including 80 patients with irritable bowel syndrome and 65 healthy controls demonstrated that Ruminococcus gnavus and Lachnospiraceae species were significantly more abundant in irritable bowel syndrome (IBS); in contrast Barnesiella intestinihominis and Coprococcus catus were less abundant in IBS (173).

 Gut-lung axis

The lung microbiota may safeguard against respiratory infections caused by Streptococcus pneumoniae and Klebsiella pneumoniae by boosting the pulmonary production of granulocyte-macrophage colony-stimulating factor (GM-CSF) via IL-17 and Nod2 activation (174). Studies on germ-free mice revealed that acute lung infections caused by K. pneumoniae, S. pneumoniae, or P. aeruginosa were associated with higher morbidity and mortality rates (174–176). Segmented filamentous bacteria are important for lung resistance against bacterial infections due to their ability to increase neutrophil numbers in the lungs during Staphylococcus aureus pneumonia and promote IL-22 and Th12 cytokine release (177). Increased gastrointestinal permeability in Chronic obstructive pulmonary disease (COPD) patients suggests the gut microbiota may contribute in worsening symptoms (178). However, the level of systemic gut microbiota-dependent TMAO has been linked to mortality, regardless of the cause of permeability (hypoxemia or pro-inflammatory state) (179). Another research discovered that early Bacteroides colonization, including B. fragilis, may serve as a precursor to asthma later in life (180).

The influence of the aforementioned dietary habits on gut microbiome diversity and abundance–and the subsequent fluctuation in microbiome-derived metabolite concentrations–demonstrates a strong correlation with disease pathology. This dynamic, conceptualized as the “Diet-Microbiome-Metabolome-Disease” axis, functions to either mitigate or exacerbate disease states. Tables 1, 2 synthesize findings from individual studies to delineate the specific protective or deleterious effects arising from these diet-microbiome interactions.

The dietary source - gut microbiota – metabolites axis that protects against diseases.

Groups of gut metabolites Microbial metabolites Dietary sources Gut microbes Function Protective against disease References
Short chain fatty acids Butyrate, acetate, propionate, 2-methyl propionate, iso-valerate, valerate, iso-butyrate, succinate Apples, banana, pears, garlic, onion, sweet potatoes, oats, barley, millet, beans, lentils, chickpeas, soy, cheese, butter, yogurt, kimchi, kefir, almonds, flax seeds, chia seeds Bifidobacteria bifidum, Bifidobacteria infantis, Bifidobacteria breve, Faecalibacterium prausnitzii, Akkermansia muciniphila, Clostridium leptum, Prevotella spp., Veillonella spp., Eubacterium hallii, Eubacterium rectale, Coprococcus spp., Dialister spp., Megasphaera elsdenii, Roseburia intestinalis, Roseburia inilivorans and Bacteroides spp. Fiber fermentation, gut barrier integrity, circadian rhythms, inhibition of pro-inflammatory cytokines, improve insulin sensitivity, synthesis of vitamin B, maintain gut-brain axis, and modulation of the systemic immune response. Protective against autism spectrum disorder, sclerosis, Parkinson’s disease, asthma, diabetes, obesity, pancreatitis, non-alcoholic fatty liver disease, hypertension, atherosclerosis, chronic kidney disease, ulcerative colitis, Crohn’s disease, colorectal cancer (12, 66, 67, 127, 128, 137, 150, 171, 180, 182–213)
Tryptophan and indole derivatives Kynurenine, tryptamine, serotonin, indole-3-lactic acid, indole-3-acetic acid, indole-3-acetamide, indole, indole-3-propionic acid. Fish, salmon, poultry eggs, red meat, chicken, beef, pork, cauliflower, cabbage, broccoli, dates, chocolate, yogurt, cheese, soybeans, oats, almonds, peanuts, chickpeas, sunflower seeds, chia seeds, sesame seed., Bacillus, Pseudomonas aeruginosa, Streptomyces, Candida, Escherichia coli, Enterococcus faecalis, Streptococcus, Clostridium spp., Bacteroides spp., Lactobacillus, Bifidobacterium, Staphylococcus, Peptostreptococcus, Lactococcus, Klebsiella, Ralstonia, Ruminococcus, Blautia, Citrobacter, Edwardsiella, and Providencia Affect the virulence, drug resistance, biofilm development, and spore formation of gut microorganisms; control the functions of the intestinal barrier, gut hormone secretion, gut motility, and systemic immune response. Protective against irritable bowel syndrome, migraine, schizophrenia, Alzheimer’s disease, Parkinson’s disease, autism spectrum disorder, obesity (115, 117, 214–239)
Neurotransmitter Gamma amino butyric acid, dopamine, glutamate, catecholamine, 5-hydroxy tryptamine Kimchi, miso, fermented food, tomato, spinach, broccoli, lentils, whole grains, sunflower seeds, soybeans, walnut, avocado, almonds, dark chocolate, fish specially shrimp, halibut Parabacteroides, Eubacterium, Lactobacillus brevis, Bacteroides, Bifidobacterium, Prevotella, Ruminococcus, Clostridium, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Blautia, Bacteroides fragilis Control nervous system immunity, memory, stress reactions, and gastrointestinal motility. Protective against Parkinson’s disease, Alzheimer’s disease (240–258)

The Dietary source - gut microbiota – metabolites axis that promotes diseases.

Groups of gut metabolites Microbial metabolites Dietary sources Gut microbes Function Protective against disease References
Choline metabolites Dimethylglycine, acetyl choline, dimethylamine, methylamine, and trimethylamine Red meat, salt water fish, chicken, egg, beef, pork, lamb Acinetobacter baumannii, Acinetobacter calcoaceticus Pelobacter carbinolicus, Pelobacter acetylenicus, Fusobacterium, Desulfovibrio, Prevotella, Mitsuokella Inhibits the production of bile acids; increases thrombosis, inflammation; influences cardiac fibrosis, hypertrophy; and aggravates mitochondrial dysfunction Promotes obesity, atherosclerosis, diabetes, heart failure, hypertension, and non-alcoholic fatty liver disease (213, 259–279)
Lipids Cholesterol, triglyceride, lipopolysaccharide, phosphatidylcholines. Processed meat like sausage, poultry, milk, cheese, yogurt, cream, butter, ghee, margarine Escherichia coli, Salmonella, Shigella, Yersinia pestis, Brucella abortus, Lactobacillus, Eubacterium coprostanoligenes Systemic inflammation is triggered by lipoprotein profiles, immunological system, and hyperinsulinemia are regulated by conjugated fatty acids; cholesterol serves as a building block for the formation of bile acids. Promote chronic hepatitis C, diabetes, obesity, hypercholesterolemia, hyperinsulinemia, and non-alcoholic fatty liver disease. (280–290)
Discussion and conclusion

Over the past decade, a substantial body of evidence has established the critical influence of gut-microbiota-derived metabolites, the composition of the gut microbiome, and dietary inputs on human health and disease states. Progress in elucidating host–microbiome and microbially mediated metabolic interactions, together with the advent of multi-omics platforms, is poised to significantly advance mechanistic insights into these multifaceted systems. However, existing research continues to be hampered by methodological and analytical shortcomings, frequently resulting in inconsistent or equivocal findings. Addressing these challenges will require the adoption of integrative, methodologically rigorous strategies aimed at refining current analytical paradigms, thereby enabling more robust mechanistic interpretation of gut microbiome data within the context of disease pathogenesis.

This review highlights that deciphering the complex diet-gut-microbiome-serum metabolome interplay demands advanced deep sequencing strategies beyond conventional methods. The 16S rDNA sequencing approach, though widely used, is inherently constrained by its inability to resolve microbial identity beyond the genus level and its lack of explanatory power regarding strain-specific diversity. In contrast, whole genome metagenomic sequencing provides comprehensive species and strain level insights, enabling precise characterization of microbial functions and the discovery of health-associated biomarkers. Consequently, high-throughput shotgun metagenomic sequencing becomes essential for capturing the subtle microbial variations and functional pathways that underpin human health and disease (181).

To decode the complex interplay among diet, microbiota, and serum metabolites, integrative network analyses incorporating multi-omics data genomics, proteomics, transcriptomics, and metabolomics are imperative. These multi-layered approaches facilitate a systems-level understanding, allowing the development of predictive models of host-microbe interactions and their implications in pathology. Currently, most microbiome studies predominantly explore bacterial components; however, expanding research to encompass viruses, fungi, archaea, and protists will provide a more holistic view of microbiota ecology and its influence on human health.

Furthermore, host genetic factors, including polymorphisms and epigenetic modifications, are increasingly recognized as modulators of microbiome composition and activity, underscoring the importance of an integrated host-microbe perspective. Cross-organ microbiota comparisons, such as the skin and oral microbiomes, may uncover systemic pathways through which microbial communities influence overall physiology and disease susceptibility.

Ultimately, this conceptual framework posits that dietary patterns modulate the gut microbiota, which in turn functions as a dynamic bioreactor via microbial metabolism to produce signaling molecules that manifest as serum metabolites. This diet-microbiome-metabolome axis epitomizes a central hub in human physiology, with profound implications for precision nutrition. Personalized dietary interventions, leveraging insights from multi-omics datasets, hold promise for promoting eubiosis, optimizing metabolomic profiles, and mitigating disease risk. Future research should prioritize elucidating dose-response relationships between specific dietary components, such as fiber and polyphenols, and the systemic bioavailability of beneficial microbial metabolites. Therapeutic strategies ranging from prebiotics and postbiotics to targeted microbiota modulation aim to achieve predictable, durable health outcomes throughout the human lifespan.

 Author contributions

SR: Investigation, Writing – original draft. PS: Conceptualization, Methodology, Supervision, Writing – original draft, Writing – review & editing.

 Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Generative AI statement

The author(s) declared that generative AI was used in the creation of this manuscript. As reviewers suggested to improve the clarity and color contrast of the Fig-2 for better readability, the originally submitted image was recreated with Gemini AI to improve the color contrast and clarity.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Bul M Plummer N. Part 1: the human gut microbiome in health and disease. Integr Med. (2014) 13:17–22. Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut. (1998) 42:2–7. 10.1136/gut.42.1.2 9505873 Bäckhed F Ley R Sonnenburg J Peterson D Gordon J. Host-bacterial mutualism in the human intestine. Science. (2005) 307:1915–20. 10.1126/science.1104816 15790844 Neish A. Microbes in gastrointestinal health and disease. Gastroenterology. (2009) 136:65–80. 10.1053/j.gastro.2008.10.080 19026645 Qin J Li R Raes J Arumugam M Burgdorf K Manichanh C A human gut microbial gene catalogue established by metagenomic sequencing. Nature. (2010) 464:59–65. 10.1038/nature08821 20203603 Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. (2012) 486:207–14. 10.1038/nature11234 22699609 Turnbaugh P Hamady M Yatsunenko T Cantarel B Duncan A Ley R A core gut microbiome in obese and lean twins. Nature. (2009) 457:480–4. 10.1038/nature07540 19043404 Wheeler D Srinivasan M Egholm M Shen Y Chen L McGuire A The complete genome of an individual by massively parallel DNA sequencing. Nature. (2008) 452:872–6. 10.1038/nature06884 18421352 Singh R Chang H Yan D Lee K Ucmak D Wong K Influence of diet on the gut microbiome and implications for human health. J Transl Med. (2017) 15:73. 10.1186/s12967-017-1175-y 28388917 Fujisaka S Watanabe Y Tobe K. The gut microbiome: a core regulator of metabolism. J Endocrinol. (2023) 256:e220111. 10.1530/JOE-22-0111 36458804 Morrison D Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. (2016) 7:189–200. 10.1080/19490976.2015.1134082 26963409 Louis P Hold G Flint H. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. (2014) 12:661–72. 10.1038/nrmicro3344 25198138 Richards L Li M van Esch B Garssen J Folkerts G. The effects of short-chain fatty acids on the cardiovascular system. PharmaNutrition. (2016) 4:68–111. 10.1016/j.phanu.2016.02.001 Koh A De Vadder F Kovatcheva-Datchary P Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. (2016) 165:1332–45. 10.1016/j.cell.2016.05.041 27259147 Knip M Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. Nat Rev Endocrinol. (2016) 12:154–67. 10.1038/nrendo.2015.218 26729037 Shimizu J Kubota T Takada E Takai K Fujiwara N Arimitsu N Propionate-producing bacteria in the intestine may associate with skewed responses of IL10-producing regulatory T cells in patients with relapsing polychondritis. PLoS One. (2018) 13:e0203657. 10.1371/journal.pone.0203657 30235279 El Hage R Hernandez-Sanabria E Calatayud Arroyo M Props R Van de Wiele T. Propionate-producing consortium restores antibiotic-induced dysbiosis in a dynamic in vitro model of the human intestinal microbial ecosystem. Front Microbiol. (2019) 10:1206. 10.3389/fmicb.2019.01206 31214145 Barcenilla A Pryde S Martin J Duncan S Stewart C Henderson C Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol. (2000) 66:1654–61. 10.1128/AEM.66.4.1654-1661.2000 10742256 Louis P Duncan S McCrae S Millar J Jackson M Flint H. Restricted distribution of the butyrate kinase pathway among butyrate-producing bacteria from the human colon. J Bacteriol. (2004) 186:2099–106. 10.1128/JB.186.7.2099-2106.2004 15028695 Eid N Enani S Walton G Corona G Costabile A Gibson G The impact of date palm fruits and their component polyphenols, on gut microbial ecology, bacterial metabolites and colon cancer cell proliferation. J Nutr Sci. (2014) 3:e46. 10.1017/jns.2014.16 26101614 Francavilla R Calasso M Calace L Siragusa S Ndagijimana M Vernocchi P Effect of lactose on gut microbiota and metabolome of infants with cow’s milk allergy. Pediatr Allergy Immunol. (2012) 23:420–7. 10.1111/j.1399-3038.2012.01286.x 22435727 Costabile A Klinder A Fava F Napolitano A Fogliano V Leonard C Whole-grain wheat breakfast cereal has a prebiotic effect on the human gut microbiota: a double-blind, placebo-controlled, crossover study. Br J Nutr. (2008) 99:110–20. 10.1017/S0007114507793923 17761020 Carvalho-Wells A Helmolz K Nodet C Molzer C Leonard C McKevith B Determination of the in vivo prebiotic potential of a maize-based whole grain breakfast cereal: a human feeding study. Br J Nutr. (2010) 104:1353–6. 10.1017/S0007114510002084 20487589 Walker A Ince J Duncan S Webster L Holtrop G Ze X Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. (2011) 5:220–30. 10.1038/ismej.2010.118 20686513 Keim N Martin R. Dietary whole grain–microbiota interactions: insights into mechanisms for human health. Adv Nutr. (2014) 5:556–7. 10.3945/an.114.006536 25469393 Leitch E Walker A Duncan S Holtrop G Flint H. Selective colonization of insoluble substrates by human faecal bacteria. Environ Microbiol. (2007) 9:667–79. 10.1111/j.1462-2920.2006.01186.x 17298367 Chen H Yu Y Wang J Lin Y Kong X Yang C Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. Am J Clin Nutr. (2013) 97:1044–52. 10.3945/ajcn.112.046607 23553152 Duncan S Lobley G Holtrop G Ince J Johnstone A Louis P Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes. (2008) 32:1720–4. 10.1038/ijo.2008.155 18779823 Świątecka D Narbad A Ridgway K Kostyra H. The study on the impact of glycated pea proteins on human intestinal bacteria. Int J Food Microbiol. (2011) 145:267–72. 10.1016/j.ijfoodmicro.2011.01.002 21276631 Meddah A Yazourh A Desmet I Risbourg B Verstraete W Romond M. The regulatory effects of whey retentate from bifidobacteria fermented milk on the microbiota of the Simulator of the Human intestinal microbial ecosystem (SHIME). J Appl Microbiol. (2001) 91:1110–7. 10.1046/j.1365-2672.2001.01482.x 11851820 Romond M Ais A Guillemot F Bounouader R Cortot A Romond C. Cell-free whey from milk fermented with Bifidobacterium breve C50 used to modify the colonic microflora of healthy subjects. J Dairy Sci. (1998) 81:1229–35. 10.3168/jds.S0022-0302(98)75683-8 9621224 Kim C Park J Kim M. Gut microbiota-derived short-chain Fatty acids, T cells, and inflammation. Immune Netw. (2014) 14:277–88. 10.4110/in.2014.14.6.277 25550694 David L Maurice C Carmody R Gootenberg D Button J Wolfe B Diet rapidly and reproducibly alters the human gut microbiome. Nature. (2014) 505:559–63. 10.1038/nature12820 24336217 Cotillard A Kennedy S Kong L Prifti E Pons N Le Chatelier E Dietary intervention impact on gut microbial gene richness. Nature. (2013) 500:585–8. 10.1038/nature12480 23985875 Clarke S Murphy E O’Sullivan O Lucey A Humphreys M Hogan A Exercise and associated dietary extremes impact on gut microbial diversity. Gut. (2014) 63:1913–20. 10.1136/gutjnl-2013-306541 25021423 Hildebrandt M Hoffmann C Sherrill-Mix S Keilbaugh S Hamady M Chen Y High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. (2009) 137:1716–24.e1-2. 10.1053/j.gastro.2009.08.042 19706296 De Filippo C Cavalieri D Di Paola M Ramazzotti M Poullet J Massart S Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. (2010) 107:14691–6. 10.1073/pnas.1005963107 20679230 Russell W Gratz S Duncan S Holtrop G Ince J Scobbie L High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. Am J Clin Nutr. (2011) 93:1062–72. 10.3945/ajcn.110.002188 21389180 De Filippis F Pellegrini N Vannini L Jeffery I La Storia A Laghi L High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut. (2016) 65:1812–21. 10.1136/gutjnl-2015-309957 26416813 Gao K Mu C Farzi A Zhu W. Tryptophan metabolism: a link between the gut microbiota and brain. Adv Nutr. (2020) 11:709–23. 10.1093/advances/nmz127 31825083 Chen Y Xu J Chen Y. Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders. Nutrients. (2021) 13:2099. 10.3390/nu13062099 34205336 Miri S Yeo J Abubaker S Hammami R. Neuromicrobiology, an emerging neurometabolic facet of the gut microbiome? Front Microbiol. (2023) 14:1098412. 10.3389/fmicb.2023.1098412 36733917 Levine M Suarez J Brandhorst S Balasubramanian P Cheng C Madia F Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab. (2014) 19:407–17. 10.1016/j.cmet.2014.02.006 24606898 Stamler J Daviglus M Garside D Dyer A Greenland P Neaton J. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA. (2000) 284:311–8. 10.1001/jama.284.3.311 10891962 Kris-Etherton P Harris W Appel L. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. (2002) 106:2747–57. 10.1161/01.cir.0000038493.65177.94 12438303 Simopoulos A. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. (2002) 21:495–505. 10.1080/07315724.2002.10719248 12480795 Trumbo P Schlicker S Yates A Poos M. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc. (2002) 102:1621–30. 10.1016/s0002-8223(02)90346-9 12449285 Fava F Gitau R Griffin B Gibson G Tuohy K Lovegrove J. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome ‘at-risk’ population. Int J Obes. (2013) 37:216–23. 10.1038/ijo.2012.33 22410962 Murphy E Cotter P Healy S Marques T O’Sullivan O Fouhy F Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut. (2010) 59:1635–42. 10.1136/gut.2010.215665 20926643 Shen J Zuo Z Mao A. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. (2014) 20:21–35. 10.1097/01.MIB.0000437495.30052.be 24280877 Foligné B Parayre S Cheddani R Famelart M Madec M Plé C Immunomodulation properties of multi-species fermented milks. Food Microbiol. (2016) 53:60–9. 10.1016/j.fm.2015.04.002 26611170 Rocha-Ramírez L Hernández-Chiñas U Moreno-Guerrero S Ramírez-Pacheco A Eslava C. Probiotic properties and immunomodulatory activity of Lactobacillus strains isolated from dairy products. Microorganisms. (2021) 9:825. 10.3390/microorganisms9040825 33924561 Matsumoto K Takada T Shimizu K Moriyama K Kawakami K Hirano K Effects of a probiotic fermented milk beverage containing Lactobacillus casei strain Shirota on defecation frequency, intestinal microbiota, and the intestinal environment of healthy individuals with soft stools. J Biosci Bioeng. (2010) 110:547–52. 10.1016/j.jbiosc.2010.05.016 20580604 He T Priebe M Zhong Y Huang C Harmsen H Raangs G Effects of yogurt and bifidobacteria supplementation on the colonic microbiota in lactose-intolerant subjects. J Appl Microbiol. (2007) 104:071010063119001. 10.1111/j.1365-2672.2007.03579.x 17927751 Zhong Y Huang C He T Harmsen H. [Effect of probiotics and yogurt on colonic microflora in subjects with lactose intolerance]. Wei Sheng Yan Jiu. (2006) 35: 587–91. Goossens D Jonkers D Russel M Stobberingh E Stockbrügger R. The effect of a probiotic drink with Lactobacillus plantarum 299v on the bacterial composition in faeces and mucosal biopsies of rectum and ascending colon. Aliment Pharmacol Ther. (2006) 23:255–63. 10.1111/j.1365-2036.2006.02749.x 16393305 Rajkumar H Mahmood N Kumar M Varikuti S Challa H Myakala S. Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial. Mediators Inflamm. (2014) 2014:348959. 10.1155/2014/348959 24795503 Pérez-Jiménez J Neveu V Vos F Scalbert A. Identification of the 100 richest dietary sources of polyphenols: an application of the phenol-explorer database. Eur J Clin Nutr. (2010) 64:S112–20. 10.1038/ejcn.2010.221 21045839 Queipo-Ortuño M Boto-Ordóñez M Murri M Gomez-Zumaquero J Clemente-Postigo M Estruch R Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. Am J Clin Nutr. (2012) 95:1323–34. 10.3945/ajcn.111.027847 22552027 Parkar S Stevenson D Skinner M. The potential influence of fruit polyphenols on colonic microflora and human gut health. Int J Food Microbiol. (2008) 124:295–8. 10.1016/j.ijfoodmicro.2008.03.017 18456359 Cueva C Sánchez-Patán F Monagas M Walton G Gibson G Martín-Álvarez P In vitro fermentation of grape seed flavan-3-ol fractions by human faecal microbiota: changes in microbial groups and phenolic metabolites. FEMS Microbiol Ecol. (2013) 83:792–805. 10.1111/1574-6941.12037 23121387 Tzounis X Rodriguez-Mateos A Vulevic J Gibson G Kwik-Uribe C Spencer J. Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. Am J Clin Nutr. (2011) 93:62–72. 10.3945/ajcn.110.000075 21068351 Lee H Jenner A Low C Lee Y. Effect of tea phenolics and their aromatic fecal bacterial metabolites on intestinal microbiota. Res Microbiol. (2006) 157:876–84. 10.1016/j.resmic.2006.07.004 16962743 Tomova A Bukovsky I Rembert E Yonas W Alwarith J Barnard N The effects of vegetarian and vegan diets on gut microbiota. Front Nutr. (2019) 6:47. 10.3389/fnut.2019.00047 31058160 Patterson A Mulder I Travis A Lan A Cerf-Bensussan N Gaboriau-Routhiau V Human gut symbiont roseburia hominis promotes and regulates innate immunity. Front Immunol. (2017) 8:1166. 10.3389/fimmu.2017.01166 29018440 Chang S Shen M Liu C Pu C Hu J Huang C. A gut butyrate-producing bacterium Butyricicoccus pullicaecorum regulates short-chain fatty acid transporter and receptor to reduce the progression of 1,2-dimethylhydrazine-associated colorectal cancer. Oncol Lett. (2020) 20:327. 10.3892/ol.2020.12190 33101496 Geirnaert A Calatayud M Grootaert C Laukens D Devriese S Smagghe G Butyrate-producing bacteria supplemented in vitro to Crohn’s disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity. Sci Rep. (2017) 7:11450. 10.1038/s41598-017-11734-8 28904372 Flint H Scott K Duncan S Louis P Forano E. Microbial degradation of complex carbohydrates in the gut. Gut Microbes. (2012) 3:289–306. 10.4161/gmic.19897 22572875 Shondelmyer K Knight R Sanivarapu A Ogino S Vanamala J. Ancient thali diet: gut microbiota, immunity, and health. Yale J Biol Med. (2018) 91:177–84. Atreya R Neurath M. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol. (2005) 28:187–96. 10.1385/CRIAI:28:3:187 16129903 Musial C Kuban-Jankowska A Gorska-Ponikowska M. Beneficial properties of green tea catechins. Int J Mol Sci. (2020) 21:1744. 10.3390/ijms21051744 32143309 Lopez-Legarrea P Fuller N Zulet M Martinez J Caterson I. The influence of Mediterranean, carbohydrate and high protein diets on gut microbiota composition in the treatment of obesity and associated inflammatory state. Asia Pac J Clin Nutr. (2014) 23:360–8. 10.6133/apjcn.2014.23.3.16 25164445 Bialonska D Ramnani P Kasimsetty S Muntha K Gibson G Ferreira D. The influence of pomegranate by-product and punicalagins on selected groups of human intestinal microbiota. Int J Food Microbiol. (2010) 140:175–82. 10.1016/j.ijfoodmicro.2010.03.038 20452076 Furet J Kong L Tap J Poitou C Basdevant A Bouillot J Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. (2010) 59:3049–57. 10.2337/db10-0253 20876719 Koloverou E Panagiotakos D Pitsavos C Chrysohoou C Georgousopoulou E Grekas A Adherence to Mediterranean diet and 10-year incidence (2002-2012) of diabetes: correlations with inflammatory and oxidative stress biomarkers in the ATTICA cohort study. Diabetes Metab Res Rev. (2016) 32:73–81. 10.1002/dmrr.2672 26104243 Helmus D Thompson C Zelenskiy S Tucker T Li L. Red meat-derived heterocyclic amines increase risk of colon cancer: a population-based case-control study. Nutr Cancer. (2013) 65:1141–50. 10.1080/01635581.2013.834945 24168237 Karačić A Dikarlo P Dorst I Renko I Liberati Pršo A. The gut microbiome without any plant food? A case study on the gut microbiome of a healthy carnivore. Microbiota Host. (2024) 2: 10.1530/MAH-24-0006 Larsson S Ericson U Dekkers K Arage G Rašo L Sayols-Baixeras S Meat intake in relation to composition and function of gut microbiota. Clin Nutr. (2025) 45:124–33. 10.1016/j.clnu.2024.12.034 39798223 Zhou Q Pang G Zhang Z Yuan H Chen C Zhang N Association between gut akkermansia and metabolic syndrome is dose-dependent and affected by microbial interactions: a cross-sectional study. Diabetes Metab Syndr Obes. (2021) 14:2177–88. 10.2147/DMSO.S311388 34040404 Cuevas-Sierra A Milagro F Aranaz P Martínez J Riezu-Boj J. Gut microbiota differences according to ultra-processed food consumption in a spanish population. Nutrients. (2021) 13:2710. 10.3390/nu13082710 34444870 Martínez Steele E Juul F Neri D Rauber F Monteiro C. Dietary share of ultra-processed foods and metabolic syndrome in the US adult population. Prev Med. (2019) 125:40–8. 10.1016/j.ypmed.2019.05.004 31077725 Fitzpatrick J Gibson P Taylor K Halmos E. The effect of dietary emulsifiers and thickeners on intestinal barrier function and its response to acute stress in healthy adult humans: a randomised controlled feeding study. Aliment Pharmacol Ther. (2024) 60:863–75. 10.1111/apt.18172 39072856 Wu X Tian J Wang S. Insight into non-pathogenic Th17 cells in autoimmune diseases. Front Immunol. (2018) 9:1112. 10.3389/fimmu.2018.01112 29892286 Chen P Tang X. Gut microbiota as regulators of Th17/treg balance in patients with myasthenia gravis. Front Immunol. (2021) 12:803101. 10.3389/fimmu.2021.803101 35003133 Pang A Pu S Pan Y Huang N Li D. Short-chain fatty acids from gut microbiota restore Th17/Treg balance in rheumatoid arthritis: mechanisms and therapeutic potential. J Transl Autoimmun. (2025) 11:100316. 10.1016/j.jtauto.2025.100316 41036443 Li G Xiong Y Li Z Yu Q Li S Xie J Gut microbiota-derived metabolites modulate Treg/Th17 balance: novel therapeutic targets in autoimmune diseases. Front Immunol. (2025) 16:1710733. 10.3389/fimmu.2025.1710733 41293163 Choden T Cohen N. The gut microbiome and the immune system. Explor Med. (2022):219–33. 10.37349/emed.2022.00087 Vignali D Collison L Workman C. How regulatory T cells work. Nat Rev Immunol. (2008) 8:523–32. 10.1038/nri2343 18566595 Atarashi K Tanoue T Shima T Imaoka A Kuwahara T Momose Y Induction of colonic regulatory T cells by indigenous clostridium species. Science. (2011) 331:337–41. 10.1126/science.1198469 21205640 Round J Lee S Li J Tran G Jabri B Chatila T The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science. (2011) 332:974–7. 10.1126/science.1206095 21512004 Lathrop S Bloom S Rao S Nutsch K Lio C Santacruz N Peripheral education of the immune system by colonic commensal microbiota. Nature. (2011) 478:250–4. 10.1038/nature10434 21937990 Wei B Su T Dalwadi H Stephan R Fujiwara D Huang T Resident enteric microbiota and CD8+ T cells shape the abundance of marginal zone B cells. Eur J Immunol. (2008) 38:3411–25. 10.1002/eji.200838432 19009526 Fujiwara D Wei B Presley L Brewer S McPherson M Lewinski M Systemic control of plasmacytoid dendritic cells by CD8+ T cells and commensal microbiota. J Immunol. (2008) 180:5843–52. 10.4049/jimmunol.180.9.5843 18424703 Wei B Wingender G Fujiwara D Chen D McPherson M Brewer S Commensal microbiota and CD8+ T cells shape the formation of invariant NKT cells. J Immunol. (2010) 184:1218–26. 10.4049/jimmunol.0902620 20048124 Xu H Liu M Cao J Li X Fan D Xia Y The dynamic interplay between the gut microbiota and autoimmune diseases. J Immunol Res. (2019) 2019:7546047. 10.1155/2019/7546047 31772949 Krasselt M Baerwald C. Sex, symptom severity, and quality of life in rheumatology. Clin Rev Allergy Immunol. (2019) 56:346–61. 10.1007/s12016-017-8631-6 28795307 Chen J Wright K Davis J Jeraldo P Marietta E Murray J An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med. (2016) 8:43. 10.1186/s13073-016-0299-7 27102666 Maeda Y Takeda K. Role of gut microbiota in rheumatoid arthritis. J Clin Med. (2017) 6:60. 10.3390/jcm6060060 28598360 Núñez-Sánchez M Melgar S O’Donoghue K Martínez-Sánchez M Fernández-Ruiz V Ferrer-Gómez M Crohn’s disease, host-microbiota interactions, and immunonutrition: dietary strategies targeting gut microbiome as novel therapeutic approaches. Int J Mol Sci. (2022) 23:8361. 10.3390/ijms23158361 35955491 Brown C Davis-Richardson A Giongo A Gano K Crabb D Mukherjee N Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One. (2011) 6:e25792. 10.1371/journal.pone.0025792 22043294 Bäckhed F Roswall J Peng Y Feng Q Jia H Kovatcheva-Datchary P Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe. (2015) 17:690–703. 10.1016/j.chom.2015.04.004 25974306 Madan J Hoen A Lundgren S Farzan S Cottingham K Morrison H Association of cesarean delivery and formula supplementation with the intestinal microbiome of 6-week-old infants. JAMA Pediatr. (2016) 170:212–9. 10.1001/jamapediatrics.2015.3732 26752321 Reyman M van Houten M van Baarle D Bosch A Man W Chu M Impact of delivery mode-associated gut microbiota dynamics on health in the first year of life. Nat Commun. (2019) 10:4997. 10.1038/s41467-019-13014-7 31676793 Pronovost G Hsiao E. Perinatal interactions between the microbiome, immunity, and neurodevelopment. Immunity. (2019) 50:18–36. 10.1016/j.immuni.2018.11.016 30650376 Sordillo J Korrick S Laranjo N Carey V Weinstock G Gold D Association of the infant gut microbiome with early childhood neurodevelopmental outcomes: an ancillary study to the VDAART randomized clinical trial. JAMA Netw Open. (2019) 2:e190905. 10.1001/jamanetworkopen.2019.0905 30901046 Warner B. The contribution of the gut microbiome to neurodevelopment and neuropsychiatric disorders. Pediatr Res. (2019) 85:216–24. 10.1038/s41390-018-0191-9 30283047 Parker A Fonseca S Carding S. Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health. Gut Microbes. (2020) 11:135–57. 10.1080/19490976.2019.1638722 31368397 Cerdó T Diéguez E Campoy C. Impact of gut microbiota on neurogenesis and neurological diseases during infancy. Curr Opin Pharmacol. (2020) 50:33–7. 10.1016/j.coph.2019.11.006 31864102 Erny D Hrabì de Angelis A Jaitin D Wieghofer P Staszewski O David E Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. (2015) 18:965–77. 10.1038/nn.4030 26030851 Hoban A Stilling R Ryan F Shanahan F Dinan T Claesson M Regulation of prefrontal cortex myelination by the microbiota. Transl Psychiatry. (2016) 6:e774. 10.1038/tp.2016.42 27045844 Duncan I Watters J. Remyelination and the gut-brain axis. Proc Natl Acad Sci U S A. (2019) 116:24922–4. 10.1073/pnas.1918897116 31767768 Ma Q Xing C Long W Wang H Liu Q Wang R. Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis. J Neuroinflammation. (2019) 16:53. 10.1186/s12974-019-1434-3 30823925 Skonieczna-Żydecka K Marlicz W Misera A Koulaouzidis A Łoniewski I. Microbiome-the missing link in the gut-brain axis: focus on its role in gastrointestinal and mental health. J Clin Med. (2018) 7:521. 10.3390/jcm7120521 30544486 Laue H Coker M Madan J. The developing microbiome from birth to 3 years: the gut-brain axis and neurodevelopmental outcomes. Front Pediatr. (2022) 10:815885. 10.3389/fped.2022.815885 35321011 Carabotti M Scirocco A Maselli M Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. (2015) 28:203–9. Appleton J. The gut-brain axis: influence of microbiota on mood and mental health. Integr Med. (2018) 17:28–32. Kaur H Bose C Mande S. Tryptophan metabolism by gut microbiome and gut-brain-axis: an in silico analysis. Front Neurosci. (2019) 13:1365. 10.3389/fnins.2019.01365 31920519 Cryan J Dinan T. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. (2012) 13:701–12. 10.1038/nrn3346 22968153 Rogers G Keating D Young R Wong M Licinio J Wesselingh S. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol Psychiatry. (2016) 21:738–48. 10.1038/mp.2016.50 27090305 Jiang H Zhang X Yu Z Zhang Z Deng M Zhao J Altered gut microbiota profile in patients with generalized anxiety disorder. J Psychiatr Res. (2018) 104:130–6. 10.1016/j.jpsychires.2018.07.007 30029052 Valles-Colomer M Falony G Darzi Y Tigchelaar E Wang J Tito R The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. (2019) 4:623–32. 10.1038/s41564-018-0337-x 30718848 Lin P Ding B Feng C Yin S Zhang T Qi X Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder. J Affect Disord. (2017) 207:300–4. 10.1016/j.jad.2016.09.051 27741466 McIntyre R Subramaniapillai M Shekotikhina M Carmona N Lee Y Mansur R Characterizing the gut microbiota in adults with bipolar disorder: a pilot study. Nutr Neurosci. (2021) 24:173–80. 10.1080/1028415X.2019.1612555 31132957 Evans S Bassis C Hein R Assari S Flowers S Kelly M The gut microbiome composition associates with bipolar disorder and illness severity. J Psychiatr Res. (2017) 87:23–9. 10.1016/j.jpsychires.2016.12.007 27988330 Painold A Mörkl S Kashofer K Halwachs B Dalkner N Bengesser S A step ahead: exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode. Bipolar Disord. (2019) 21:40–9. 10.1111/bdi.12682 30051546 Aizawa E Tsuji H Asahara T Takahashi T Teraishi T Yoshida S Bifidobacterium and Lactobacillus counts in the gut microbiota of patients with bipolar disorder and healthy controls. Front Psychiatry. (2019) 9:730. 10.3389/fpsyt.2018.00730 30713509 Plaza-Díaz J Gómez-Fernández A Chueca N Torre-Aguilar M Gil Á Perez-Navero J Autism spectrum disorder (ASD) with and without mental regression is associated with changes in the fecal microbiota. Nutrients. (2019) 11:337. 10.3390/nu11020337 30764497 Kandeel W Meguid N Bjørklund G Eid E Farid M Mohamed S Impact of clostridium bacteria in children with autism spectrum disorder and their anthropometric measurements. J Mol Neurosci. (2020) 70:897–907. 10.1007/s12031-020-01482-2 32130666 Yang Q Liang Q Balakrishnan B Belobrajdic D Feng Q Zhang W. Role of dietary nutrients in the modulation of gut microbiota: a narrative review. Nutrients. (2020) 12:381. 10.3390/nu12020381 32023943 Stolzer I Scherer E Süß P Rothhammer V Winner B Neurath M Impact of microbiome-brain communication on neuroinflammation and neurodegeneration. Int J Mol Sci. (2023) 24:14925. 10.3390/ijms241914925 37834373 Zhou X Baumann R Gao X Mendoza M Singh S Katz Sand I Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. Cell. (2022) 185:3467–86.e16. 10.1016/j.cell.2022.08.021 36113426 Schwerdtfeger L Montini F Lanser T Ekwudo M Zurawski J Tauhid S Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med. (2025) 6:102055. 10.1016/j.xcrm.2025.102055 40185103 Zeng Q Shen J Chen K Zhou J Liao Q Lu K The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients. Sci Rep. (2020) 10:12998. 10.1038/s41598-020-69845-8 32747678 Ferreiro A Choi J Ryou J Newcomer E Thompson R Bollinger R Gut microbiome composition may be an indicator of preclinical Alzheimer’s disease. Sci Transl Med. (2023) 15:eabo2984. 10.1126/scitranslmed.abo2984 37315112 Ling Z Zhu M Yan X Cheng Y Shao L Liu X Structural and functional dysbiosis of fecal microbiota in Chinese patients with Alzheimer’s disease. Front Cell Dev Biol. (2021) 8:634069. 10.3389/fcell.2020.634069 33614635 Boertien J Pereira P Aho V Scheperjans F. Increasing comparability and utility of gut microbiome studies in Parkinson’s disease: a systematic review. J Parkinsons Dis. (2019) 9:S297–312. 10.3233/JPD-191711 31498131 Shen T Yue Y He T Huang C Qu B Lv W The association between the gut microbiota and Parkinson’s disease, a meta-analysis. Front Aging Neurosci. (2021) 13:636545. 10.3389/fnagi.2021.636545 33643026 Li S Song J Ke P Kong L Lei B Zhou J The gut microbiome is associated with brain structure and function in schizophrenia. Sci Rep. (2021) 11:9743. 10.1038/s41598-021-89166-8 33963227 Nguyen T Kosciolek T Daly R Vázquez-Baeza Y Swafford A Knight R Gut microbiome in Schizophrenia: altered functional pathways related to immune modulation and atherosclerotic risk. Brain Behav Immun. (2021) 91:245–56. 10.1016/j.bbi.2020.10.003 33098964 Zhu F Ju Y Wang W Wang Q Guo R Ma Q Metagenome-wide association of gut microbiome features for schizophrenia. Nat Commun. (2020) 11:1612. 10.1038/s41467-020-15457-9 32235826 Zhang X Pan L Zhang Z Zhou Y Jiang H Ruan B. Analysis of gut mycobiota in first-episode, drug-naïve Chinese patients with schizophrenia: a pilot study. Behav Brain Res. (2020) 379:112374. 10.1016/j.bbr.2019.112374 31759045 Cao S Zhao C Xu X Tang G Corke H Gan R Dietary plants, gut microbiota, and obesity: Effects and mechanisms. Trends Food Sci Technol. (2019) 92:194–204. 10.1016/j.tifs.2019.08.004 Million M Lagier J Yahav D Paul M. Gut bacterial microbiota and obesity. Clin Microbiol Infect. (2013) 19:305–13. 10.1111/1469-0691.12172 23452229 Aguirre M Venema K. Does the gut microbiota contribute to obesity? Going beyond the gut feeling. Microorganisms. (2015) 3:213–35. 10.3390/microorganisms3020213 27682087 Li X Huang Y Song L Xiao Y Lu S Xu J Lactobacillus plantarum prevents obesity via modulation of gut microbiota and metabolites in high-fat feeding mice. J Funct Foods. (2020) 73:104103. 10.1016/j.jff.2020.104103 Li H Liu F Lu J Shi J Guan J Yan F Probiotic mixture of Lactobacillus plantarum strains improves lipid metabolism and gut microbiota structure in high fat diet-fed mice. Front Microbiol. (2020) 11:512. 10.3389/fmicb.2020.00512 32273874 Li X Wang E Yin B Fang D Chen P Wang G Effects of Lactobacillus casei CCFM419 on insulin resistance and gut microbiota in type 2 diabetic mice. Benef Microbes. (2017) 8:421–32. 10.3920/BM2016.0167 28504567 Song W Song C Li L Wang T Hu J Zhu L Lactobacillus alleviated obesity induced by high-fat diet in mice. J Food Sci. (2021) 86:5439–51. 10.1111/1750-3841.15971 34859434 Zhang H DiBaise J Zuccolo A Kudrna D Braidotti M Yu Y Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A. (2009) 106:2365–70. 10.1073/pnas.0812600106 19164560 Zhang L Wang P Huang J Xing Y Wong F Suo J Gut microbiota and therapy for obesity and type 2 diabetes. Front Endocrinol. (2024) 15:1333778. 10.3389/fendo.2024.1333778 38596222 Gaci N Borrel G Tottey W O’Toole P Brugère J. Archaea and the human gut: new beginning of an old story. World J Gastroenterol. (2014) 20:16062–78. 10.3748/wjg.v20.i43.16062 25473158 Chaudhary P Gaci N Borrel G O’Toole P Brugère J. Molecular methods for studying methanogens of the human gastrointestinal tract: current status and future directions. Appl Microbiol Biotechnol. (2015) 99:5801–15. 10.1007/s00253-015-6739-2 26088176 Chaudhary P Conway P Schlundt J. Methanogens in humans: potentially beneficial or harmful for health. Appl Microbiol Biotechnol. (2018) 102:3095–104. 10.1007/s00253-018-8871-2 29497795 Armougom F Henry M Vialettes B Raccah D Raoult D. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PLoS One. (2009) 4:e7125. 10.1371/journal.pone.0007125 19774074 Zhou Z Sun B Yu D Zhu C. Gut microbiota: an important player in type 2 diabetes mellitus. Front Cell Infect Microbiol. (2022) 12:834485. 10.3389/fcimb.2022.834485 35242721 Lambeth S Carson T Lowe J Ramaraj T Leff J Luo L Composition, diversity and abundance of gut microbiome in prediabetes and type 2 diabetes. J Diabetes Obes. (2015) 2:108–14. 10.15436/2376-0949.15.031 26756039 Sedighi M Razavi S Navab-Moghadam F Khamseh M Alaei-Shahmiri F Mehrtash A Comparison of gut microbiota in adult patients with type 2 diabetes and healthy individuals. Microb Pathog. (2017) 111:362–9. 10.1016/j.micpath.2017.08.038 28912092 Zhang F Wang M Yang J Xu Q Liang C Chen B Response of gut microbiota in type 2 diabetes to hypoglycemic agents. Endocrine. (2019) 66:485–93. 10.1007/s12020-019-02041-5 31410749 Forslund K Hildebrand F Nielsen T Falony G Le Chatelier E Sunagawa S Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. (2015) 528:262–6. 10.1038/nature15766 26633628 Everard A Belzer C Geurts L Ouwerkerk J Druart C Bindels L Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Ac Natl Acad Sci U S A. (2013) 110:9066–71. 10.1073/pnas.1219451110 23671105 Depommier C Everard A Druart C Plovier H Van Hul M Vieira-Silva S Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. (2019) 25:1096–103. 10.1038/s41591-019-0495-2 31263284 Del Chierico F Nobili V Vernocchi P Russo A De Stefanis C Gnani D Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. (2017) 65:451–64. 10.1002/hep.28572 27028797 Feng M Chai Y Li J Wang Q Zhang D. A metagenome-wide association study of gut microbiota in hepatitis B virus-related cirrhosis in northwest China. Front Genet. (2025) 16:1619911. 10.3389/fgene.2025.1619911 40909440 Ramírez-Macías I Orenes-Piñero E Camelo-Castillo A Rivera-Caravaca J López-García C Marín F. Novel insights in the relationship of gut microbiota and coronary artery diseases. Crit Rev Food Sci Nutr. (2022) 62:3738–50. 10.1080/10408398.2020.1868397 33399007 Tuomisto S Huhtala H Martiskainen M Goebeler S Lehtimäki T Karhunen P. Age-dependent association of gut bacteria with coronary atherosclerosis: tampere sudden death study. PLoS One. (2019) 14:e0221345. 10.1371/journal.pone.0221345 31437200 Jie Z Xia H Zhong S Feng Q Li S Liang S The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. (2017) 8:845. 10.1038/s41467-017-00900-1 29018189 Jia Q Li H Zhou H Zhang X Zhang A Xie Y Role and effective therapeutic target of gut microbiota in heart failure. Cardiovasc Ther. (2019) 2019:5164298. 10.1155/2019/5164298 31819762 Chung L Thiele Orberg E Geis A Chan J Fu K DeStefano Shields C Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe. (2018) 23:203–14.e5. 10.1016/j.chom.2018.01.007 29398651 Hsieh Y Tung S Pan H Yen C Xu H Lin Y Increased abundance of clostridium and fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Sci Rep. (2018) 8:158. 10.1038/s41598-017-18596-0 29317709 Mehta R Nishihara R Cao Y Song M Mima K Qian Z Association of dietary patterns with risk of colorectal cancer subtypes classified by Fusobacterium nucleatum in tumor tissue. JAMA Oncol. (2017) 3:921–7. 10.1001/jamaoncol.2016.6374 28125762 Ranjbar M Salehi R Haghjooy Javanmard S Rafiee L Faraji H Jafarpor S The dysbiosis signature of Fusobacterium nucleatum in colorectal cancer-cause or consequences? A systematic review. Cancer Cell Int. (2021) 21:194. 10.1186/s12935-021-01886-z 33823861 Wang W Chen L Zhou R Wang X Song L Huang S Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol. (2014) 52:398–406. 10.1128/JCM.01500-13 24478468 Jeffery I Das A O’Herlihy E Coughlan S Cisek K Moore M Differences in fecal microbiomes and metabolomes of people with vs without irritable bowel syndrome and bile acid malabsorption. Gastroenterology. (2020) 158:1016–28.e8. 10.1053/j.gastro.2019.11.301 31843589 Brown R Sequeira R Clarke T. The microbiota protects against respiratory infection via GM-CSF signaling. Nat Commun. (2017) 8:1512. 10.1038/s41467-017-01803-x 29142211 Fagundes C Amaral F Vieira A Soares A Pinho V Nicoli J Transient TLR activation restores inflammatory response and ability to control pulmonary bacterial infection in germfree mice. J Immunol. (2012) 188:1411–20. 10.4049/jimmunol.1101682 22210917 Fox A McConnell K Yoseph B Breed E Liang Z Clark A The endogenous bacteria alter gut epithelial apoptosis and decrease mortality following Pseudomonas aeruginosa pneumonia. Shock. (2012) 38:508–14. 10.1097/SHK.0b013e31826e47e8 23042193 Gauguet S D’Ortona S Ahnger-Pier K Duan B Surana N Lu R Intestinal microbiota of mice influences resistance to Staphylococcus aureus pneumonia. Infect Immun. (2015) 83:4003–14. 10.1128/IAI.00037-15 26216419 Sprooten R Lenaerts K Braeken D Grimbergen I Rutten E Wouters E Increased small intestinal permeability during severe acute exacerbations of COPD. Respiration. (2018) 95:334–42. 10.1159/000485935 29393240 Ottiger M Nickler M Steuer C Bernasconi L Huber A Christ-Crain M Gut, microbiota-dependent trimethylamine-N-oxide is associated with long-term all-cause mortality in patients with exacerbated chronic obstructive pulmonary disease. Nutrition. (2018) 45:135–41.e1. 10.1016/j.nut.2017.07.001 28870405 Vael C Nelen V Verhulst S Goossens H Desager K. Early intestinal Bacteroides fragilis colonisation and development of asthma. BMC Pulm Med. (2008) 8:19. 10.1186/1471-2466-8-19 18822123 Ranjan R Rani A Metwally A McGee H Perkins D. Analysis of the microbiome: advantages of whole genome shotgun versus 16S amplicon sequencing. Biochem Biophys Res Commun. (2016) 469:967–77. 10.1016/j.bbrc.2015.12.083 26718401 Tan J McKenzie C Potamitis M Thorburn A Mackay C Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. (2014) 121:91–119. 10.1016/B978-0-12-800100-4.00003-9 24388214 Felizardo R Watanabe I Dardi P Rossoni L Câmara N. The interplay among gut microbiota, hypertension and kidney diseases: the role of short-chain fatty acids. Pharmacol Res. (2019) 141:366–77. 10.1016/j.phrs.2019.01.019 30639376 Canfora E Meex R Venema K Blaak E. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. (2019) 15:261–73. 10.1038/s41574-019-0156-z 30670819 Tahara Y Yamazaki M Sukigara H Motohashi H Sasaki H Miyakawa H Gut microbiota-derived short chain fatty acids induce circadian clock entrainment in mouse peripheral tissue. Sci Rep. (2018) 8:1395. 10.1038/s41598-018-19836-7 29362450 Dalile B Van Oudenhove L Vervliet B Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. (2019) 16:461–78. 10.1038/s41575-019-0157-3 31123355 Feng W Ao H Peng C. Gut microbiota, short-chain fatty acids, and herbal medicines. Front Pharmacol. (2018) 9:1354. 10.3389/fphar.2018.01354 30532706 Pan L Li B Pan X Sun J. Gut microbiota in pancreatic diseases: possible new therapeutic strategies. Acta Pharmacol Sin. (2021) 42:1027–39. 10.1038/s41401-020-00532-0 33093569 Fusco W Lorenzo M Cintoni M Porcari S Rinninella E Kaitsas F Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota. Nutrients. (2023) 15:2211. 10.3390/nu15092211 37432351 Tsukuda N Yahagi K Hara T Watanabe Y Matsumoto H Mori H Key bacterial taxa and metabolic pathways affecting gut short-chain fatty acid profiles in early life. ISME J. (2021) 15:2574–90. 10.1038/s41396-021-00937-7 33723382 Rios-Covian D Gueimonde M Duncan S Flint H de los Reyes-Gavilan C. Enhanced butyrate formation by cross-feeding between Faecalibacterium prausnitzii and Bifidobacterium adolescentis. FEMS Microbiol Lett. (2015) 362:fnv176. 10.1093/femsle/fnv176 26420851 Sela D Mills D. Nursing our microbiota: molecular linkages between bifidobacteria and milk oligosaccharides. Trends Microbiol. (2010) 18:298–307. 10.1016/j.tim.2010.03.008 20409714 Walsh C Lane J van Sinderen D Hickey R. Human milk oligosaccharide-sharing by a consortium of infant derived Bifidobacterium species. Sci Rep. (2022) 12:4143. 10.1038/s41598-022-07904-y 35264656 Henrick B Rodriguez L Lakshmikanth T Pou C Henckel E Arzoomand A Bifidobacteria-mediated immune system imprinting early in life. Cell. (2021) 184: 3884–98.e11. 10.1016/j.cell.2021.05.030 34143954 Saturio S Nogacka A Alvarado-Jasso G Salazar N de Los Reyes-Gavilán C Gueimonde M Role of bifidobacteria on infant health. Microorganisms. (2021) 9:2415. 10.3390/microorganisms9122415 34946017 Fukuda S Toh H Taylor T Ohno H Hattori M. Acetate-producing bifidobacteria protect the host from enteropathogenic infection via carbohydrate transporters. Gut Microbes. (2012) 3:449–54. 10.4161/gmic.21214 22825494 Deleu S Machiels K Raes J Verbeke K Vermeire S. Short chain fatty acids and its producing organisms: an overlooked therapy for IBD? EBioMedicine. (2021) 66:103293. 10.1016/j.ebiom.2021.103293 33813134 Conlon M Bird A. The impact of diet and lifestyle on gut microbiota and human health. Nutrients. (2014) 7:17–44. 10.3390/nu7010017 25545101 Reichardt N Duncan S Young P Belenguer A McWilliam Leitch C Scott K Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. ISME J. (2014) 8:1323–35. 10.1038/ismej.2014.14 24553467 Louis P Flint H. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. (2017) 19:29–41. 10.1111/1462-2920.13589 27928878 Singh V Lee G Son H Koh H Kim E Unno T Butyrate producers, the Sentinel of gut: their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics. Front Microbiol. (2023) 13:1103836. 10.3389/fmicb.2022.1103836 36713166 Louis P Young P Holtrop G Flint H. Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene. Environ Microbiol. (2010) 12:304–14. 10.1111/j.1462-2920.2009.02066.x 19807780 Schwab C Ruscheweyh H Bunesova V Pham V Beerenwinkel N Lacroix C. Trophic interactions of infant bifidobacteria and Eubacterium hallii during L-Fucose and fucosyllactose degradation. Front Microbiol. (2017) 8:95. 10.3389/fmicb.2017.00095 28194144 Martín R Bermúdez-Humarán L Langella P. Searching for the bacterial effector: the example of the multi-skilled commensal bacterium Faecalibacterium prausnitzii. Front Microbiol. (2018) 9:346. 10.3389/fmicb.2018.00346 29559959 Miquel S Martín R Rossi O Bermúdez-Humarán L Chatel J Sokol H Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol. (2013) 16:255–61. 10.1016/j.mib.2013.06.003 23831042 Machiels K Joossens M Sabino J De Preter V Arijs I Eeckhaut V A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. (2014) 63:1275–83. 10.1136/gutjnl-2013-304833 24021287 Engels C Ruscheweyh H Beerenwinkel N Lacroix C Schwab C. The common gut microbe Eubacterium hallii also contributes to intestinal propionate formation. Front Microbiol. (2016) 7:713. 10.3389/fmicb.2016.00713 27242734 Kang D Ilhan Z Isern N Hoyt D Howsmon D Shaffer M Differences in fecal microbial metabolites and microbiota of children with autism spectrum disorders. Anaerobe. (2018) 49:121–31. 10.1016/j.anaerobe.2017.12.007 29274915 Wang L Christophersen C Sorich M Gerber J Angley M Conlon M. Elevated fecal short chain fatty acid and ammonia concentrations in children with autism spectrum disorder. Dig Dis Sci. (2012) 57:2096–102. 10.1007/s10620-012-2167-7 22535281 Unger M Spiegel J Dillmann K Grundmann D Philippeit H Bürmann J Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord. (2016) 32:66–72. 10.1016/j.parkreldis.2016.08.019 27591074 Keshavarzian A Green S Engen P Voigt R Naqib A Forsyth C Colonic bacterial composition in Parkinson’s disease. Mov Disord. (2015) 30:1351–60. 10.1002/mds.26307 26179554 Hopfner F Künstner A Müller S Künzel S Zeuner K Margraf N Gut microbiota in Parkinson disease in a northern German cohort. Brain Res. (2017) 1667:41–5. 10.1016/j.brainres.2017.04.019 28506555 Duttaroy A. Role of gut microbiota and their metabolites on atherosclerosis, hypertension and human blood platelet function: a review. Nutrients. (2021) 13:144. 10.3390/nu13010144 33401598 Lee J Lee J. Indole as an intercellular signal in microbial communities. FEMS Microbiol Rev. (2010) 34:426–44. 10.1111/j.1574-6976.2009.00204.x 20070374 Roager H Licht T. Microbial tryptophan catabolites in health and disease. Nat Commun. (2018) 9:3294. 10.1038/s41467-018-05470-4 30120222 Cervantes-Barragan L Chai J Tianero M Di Luccia B Ahern P Merriman J Lactobacillus reuteri induces gut intraepithelial CD4+CD8αα+ T cells. Science. (2017) 357:806–10. 10.1126/science.aah5825 28775213 Aragozzini F Ferrari A Pacini N Gualandris R. Indole-3-lactic acid as a tryptophan metabolite produced by Bifidobacterium spp. Appl Environ Microbiol. (1979) 38:544–6. 10.1128/aem.38.3.544-546.1979 533277 Williams B Van Benschoten A Cimermancic P Donia M Zimmermann M Taketani M Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe. (2014) 16:495–503. 10.1016/j.chom.2014.09.001 25263219 Wlodarska M Luo C Kolde R d’Hennezel E Annand J Heim C Indoleacrylic acid produced by commensal peptostreptococcus species suppresses inflammation. Cell Host Microbe. (2017) 22:25–37.e6. 10.1016/j.chom.2017.06.007 28704649 Mandić A Woting A Jaenicke T Sander A Sabrowski W Rolle-Kampcyk U Clostridium ramosum regulates enterochromaffin cell development and serotonin release. Sci Rep. (2019) 9:1177. 10.1038/s41598-018-38018-z 30718836 Yano J Yu K Donaldson G Shastri G Ann P Ma L Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. (2015) 161:264–76. 10.1016/j.cell.2015.02.047 25860609 O’Mahony S Clarke G Borre Y Dinan T Cryan J. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res. (2015) 277:32–48. 10.1016/j.bbr.2014.07.027 25078296 Kennedy P Cryan J Dinan T Clarke G. Kynurenine pathway metabolism and the microbiota-gut-brain axis. Neuropharmacology. (2017) 112:399–412. 10.1016/j.neuropharm.2016.07.002 27392632 Roth W Zadeh K Vekariya R Ge Y Mohamadzadeh M. Tryptophan metabolism and gut-brain homeostasis. Int J Mol Sci. (2021) 22:2973. 10.3390/ijms22062973 33804088 Zhang J Zhu S Ma N Johnston L Wu C Ma X. Metabolites of microbiota response to tryptophan and intestinal mucosal immunity: a therapeutic target to control intestinal inflammation. Med Res Rev. (2021) 41:1061–88. 10.1002/med.21752 33174230 Modoux M Rolhion N Mani S Sokol H. Tryptophan metabolism as a pharmacological target. Trends Pharmacol Sci. (2021) 42:60–73. 10.1016/j.tips.2020.11.006 33256987 Delgado P Charney D Price L Aghajanian G Landis H Heninger G. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry. (1990) 47:411–8. 10.1001/archpsyc.1990.01810170011002 2184795 Jaglin M Rhimi M Philippe C Pons N Bruneau A Goustard B Indole, a signaling molecule produced by the gut microbiota, negatively impacts emotional behaviors in rats. Front Neurosci. (2018) 12:216. 10.3389/fnins.2018.00216 29686603 Wang L Zhang Y Ran Y Li L Mei L Ye F Association between AHR in EGCs and IBS-D patients: the indole pathway of tryptophan metabolism. Front Nutr. (2025) 12:1566595. 10.3389/fnut.2025.1566595 40225339 Körtési T Spekker E Vécsei L. Exploring the tryptophan metabolic pathways in migraine-related mechanisms. Cells. (2022) 11:3795. 10.3390/cells11233795 36497053 Shi C Dong J Hui X Xu Z Zhao Z Dong L. Production, mechanisms, and therapeutic strategies of tryptophan metabolites in CNS diseases. Mol Neurobiol. (2026) 63:226. 10.1007/s12035-025-05538-5 41324859 Huang J Tong J Zhang P Zhou Y Cui Y Tan S Effects of neuroactive metabolites of the tryptophan pathway on working memory and cortical thickness in schizophrenia. Transl Psychiatry. (2021) 11:198. 10.1038/s41398-021-01311-z 33795641 Yao J Dougherty G Reddy R Keshavan M Montrose D Matson W Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. (2010) 15:938–53. 10.1038/mp.2009.33 19401681 Owe-Larsson M Drobek D Iwaniak P Kloc R Urbanska E Chwil M. Microbiota-derived tryptophan metabolite Indole-3-propionic acid-emerging role in neuroprotection. Molecules. (2025) 30:3628. 10.3390/molecules30173628 40942152 Savonije K Weaver D. The role of tryptophan metabolism in Alzheimer’s disease. Brain Sci. (2023) 13:292. 10.3390/brainsci13020292 36831835 Fan X Xiao Z Chen Y Yang H Diao M Hu W Interactions between gut microbiota and parkinson’s disease: the role of tryptophan metabolism. Cell Commun Signal. (2025) 23:424. 10.1186/s12964-025-02393-8 41068876 Wang Y Chen S Tan J Gao Y Yan H Liu Y Tryptophan in the diet ameliorates motor deficits in a rotenone-induced rat Parkinson’s disease model via activating the aromatic hydrocarbon receptor pathway. Brain Behav. (2021) 11:e2226. 10.1002/brb3.2226 34105899 Kałużna-Czaplińska J Jóźwik-Pruska J Chirumbolo S Bjørklund G. Tryptophan status in autism spectrum disorder and the influence of supplementation on its level. Metab Brain Dis. (2017) 32:1585–93. 10.1007/s11011-017-0045-x 28608247 Lee J Jang H Lee D Lee Y Lee H. Gut bacteria-derived tryptamine ameliorates diet-induced obesity and insulin resistance in mice. Int J Mol Sci. (2025) 26:1327. 10.3390/ijms26031327 39941095 Morais L Schreiber H Mazmanian S. The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol. (2021) 19:241–55. 10.1038/s41579-020-00460-0 33093662 Wang Y Li N Yang J Zhao D Chen B Zhang G Probiotics and fructo-oligosaccharide intervention modulate the microbiota-gut brain axis to improve autism spectrum reducing also the hyper-serotonergic state and the dopamine metabolism disorder. Pharmacol Res. (2020) 157:104784. 10.1016/j.phrs.2020.104784 32305492 McCarville J Chen G Cuevas V Troha K Ayres J. Microbiota metabolites in health and disease. Annu Rev Immunol. (2020) 38:147–70. 10.1146/annurev-immunol-071219-125715 32340573 Mhanna A Martini N Hmaydoosh G Hamwi G Jarjanazi M Zaifah G The correlation between gut microbiota and both neurotransmitters and mental disorders: a narrative review. Medicine. (2024) 103:e37114. 10.1097/MD.0000000000037114 38306525 Gu F Wu Y Liu Y Dou M Jiang Y Liang H. Lactobacillus casei improves depression-like behavior in chronic unpredictable mild stress-induced rats by the BDNF-TrkB signal pathway and the intestinal microbiota. Food Funct. (2020) 11:6148–57. 10.1039/d0fo00373e 32578646 Hamamah S Aghazarian A Nazaryan A Hajnal A Covasa M. Role of microbiota-gut-brain axis in regulating dopaminergic signaling. Biomedicines. (2022) 10:436. 10.3390/biomedicines10020436 35203645 Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res. (2018) 1693:128–33. 10.1016/j.brainres.2018.03.015 29903615 Liu G Chong H Chung F Li Y Liong M. Lactobacillus plantarum DR7 modulated bowel movement and gut microbiota associated with dopamine and serotonin pathways in stressed adults. Int J Mol Sci. (2020) 21:4608. 10.3390/ijms21134608 32610495 Cui Y Miao K Niyaphorn S Qu X. Production of gamma-aminobutyric acid from lactic acid bacteria: a systematic review. Int J Mol Sci. (2020) 21:995. 10.3390/ijms21030995 32028587 Sarasa S Mahendran R Muthusamy G Thankappan B Selta D Angayarkanni J. A brief review on the non-protein amino acid, Gamma-amino butyric acid (GABA): its production and role in microbes. Curr Microbiol. (2020) 77:534–44. 10.1007/s00284-019-01839-w 31844936 Dicks L. Gut bacteria and neurotransmitters. Microorganisms. (2022) 10:1838. 10.3390/microorganisms10091838 36144440 Zhuang Z Yang R Wang W Qi L Huang T. Associations between gut microbiota and Alzheimer’s disease, major depressive disorder, and schizophrenia. J Neuroinflammation. (2020) 17:288. 10.1186/s12974-020-01961-8 33008395 Strandwitz P Kim K Terekhova D Liu J Sharma A Levering J GABA-modulating bacteria of the human gut microbiota. Nat Microbiol. (2018) 4:396–403. 10.1038/s41564-018-0307-3 30531975 Tian X Xing J Zheng Q Gao P. 919 syrup alleviates postpartum depression by modulating the structure and metabolism of gut microbes and affecting the function of the hippocampal GABA/glutamate system. Front Cell Infect Microbiol. (2021) 11:694443. 10.3389/fcimb.2021.694443 34490139 Dinan T Cryan J. The microbiome-gut-brain axis in health and disease. Gastroenterol Clin North Am. (2017) 46:77–89. 10.1016/j.gtc.2016.09.007 28164854 Klein M Battagello D Cardoso A Hauser D Bittencourt J Correa R. Dopamine: functions, signaling, and association with neurological diseases. Cell Mol Neurobiol. (2019) 39:31–59. 10.1007/s10571-018-0632-3 30446950 Barcomb K Ford C. Alterations in neurotransmitter co-release in Parkinson’s disease. Exp Neurol. (2023) 370:114562. 10.1016/j.expneurol.2023.114562 37802381 Yang Z Zou Y Wang L. Neurotransmitters in prevention and treatment of Alzheimer’s disease. Int J Mol Sci. (2023) 24:3841. 10.3390/ijms24043841 36835251 Akyuz E Arulsamy A Aslan F Sarisözen B Guney B Hekimoglu A An expanded narrative review of neurotransmitters on Alzheimer’s disease: the role of therapeutic interventions on neurotransmission. Mol Neurobiol. (2025) 62:1631–74. 10.1007/s12035-024-04333-y 39012443 Jameson E Quareshy M Chen Y. Methodological considerations for the identification of choline and carnitine-degrading bacteria in the gut. Methods. (2018) 149:42–8. 10.1016/j.ymeth.2018.03.012 29684641 Rath S Rud T Pieper D Vital M. Potential TMA-producing bacteria are ubiquitously found in mammalia. Front Microbiol. (2020) 10:2966. 10.3389/fmicb.2019.02966 31998260 Lv S Wang Y Zhang W Shang H. Trimethylamine oxide: a potential target for heart failure therapy. Heart. (2022) 108:917–22. 10.1136/heartjnl-2021-320054 34611047 Bennett B de Aguiar Vallim T Wang Z Shih D Meng Y Gregory J Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. (2013) 17:49–60. 10.1016/j.cmet.2012.12.011 23312283 Wiedeman A Barr S Green T Xu Z Innis S Kitts D. Dietary choline intake: current state of knowledge across the life cycle. Nutrients. (2018) 10:1513. 10.3390/nu10101513 30332744 Arias N Arboleya S Allison J Kaliszewska A Higarza S Gueimonde M The relationship between choline bioavailability from diet, intestinal microbiota composition, and its modulation of human diseases. Nutrients. (2020) 12:2340. 10.3390/nu12082340 32764281 Koeth R Lam-Galvez B Kirsop J Wang Z Levison B Gu X l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. J Clin Invest. (2018) 129:373–87. 10.1172/JCI94601 30530985 Zeisel S Warrier M. Trimethylamine N-oxide, the microbiome, and heart and kidney disease. Annu Rev Nutr. (2017) 37:157–81. 10.1146/annurev-nutr-071816-064732 28715991 Wang Z Bergeron N Levison B Li X Chiu S Jia X Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine N-oxide metabolism and renal excretion in healthy men and women. Eur Heart J. (2019) 40:583–94. 10.1093/eurheartj/ehy799 30535398 Zhang Y Wang Y Ke B Du J. TMAO: how gut microbiota contributes to heart failure. Transl Res. (2021) 228:109–25. 10.1016/j.trsl.2020.08.007 32841736 Yang S Li X Yang F Zhao R Pan X Liang J Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target. Front Pharmacol. (2019) 10:1360. 10.3389/fphar.2019.01360 31803054 Zhu W Gregory J Org E Buffa J Gupta N Wang Z Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. (2016) 165:111–24. 10.1016/j.cell.2016.02.011 26972052 Schugar R Willard B Wang Z Brown J. Postprandial gut microbiota-driven choline metabolism links dietary cues to adipose tissue dysfunction. Adipocyte. (2018) 7:49–56. 10.1080/21623945.2017.1398295 29172946 Pan X Yang J Shu X Moore S Palmer N Guasch-Ferré M Associations of circulating choline and its related metabolites with cardiometabolic biomarkers: an international pooled analysis. Am J Clin Nutr. (2021) 114:893–906. 10.1093/ajcn/nqab152 34020444 Sprinkles J Lulla A Hullings A Trujillo-Gonzalez I Klatt K Jacobs D Choline metabolites and 15-year risk of incident diabetes in a prospective cohort of adults: coronary artery risk development in young adults (CARDIA) study. Diabetes Care. (2024) 47:1985–94. 10.2337/dc24-1033 39259767 Zhou S Xue J Shan J Hong Y Zhu W Nie Z Gut-flora-dependent metabolite Trimethylamine-N-oxide promotes atherosclerosis-associated inflammation responses by indirect ROS stimulation and signaling involving AMPK and SIRT1. Nutrients. (2022) 14:3338. 10.3390/nu14163338 36014845 Geng J Yang C Wang B Zhang X Hu T Gu Y Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway. Biomed Pharmacother. (2018) 97:941–7. 10.1016/j.biopha.2017.11.016 29136772 Organ C Otsuka H Bhushan S Wang Z Bradley J Trivedi R Choline diet and its gut microbe-derived metabolite, Trimethylamine N-Oxide, exacerbate pressure overload-induced heart failure. Circ Heart Fail. (2016) 9:e002314. 10.1161/CIRCHEARTFAILURE.115.002314 26699388 Yang Y Yang B Liu B Liang Y Luo Q Zhao Z Circulating choline levels are associated with prognoses in patients with pulmonary hypertension: a cohort study. BMC Pulm Med. (2023) 23:313. 10.1186/s12890-023-02547-9 37689632 Guo F Qiu X Zhu Y Tan Z Li Z Ouyang D. Circulating choline is associated with coronary artery stenosis in patients with hypertension: a cross-sectional study of Chinese adults. J Clin Hypertens. (2020) 22:2069–76. 10.1111/jch.14025 32966687 Chen Y Liu Y Zhou R Chen X Wang C Tan X Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep. (2016) 6:19076. 10.1038/srep19076 26743949 Serino M Luche E Gres S Baylac A Bergé M Cenac C Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut. (2012) 61:543–53. 10.1136/gutjnl-2011-301012 22110050 Fuke N Nagata N Suganuma H Ota T. Regulation of gut microbiota and metabolic endotoxemia with dietary factors. Nutrients. (2019) 11:2277. 10.3390/nu11102277 31547555 Kapourchali F Surendiran G Goulet A Moghadasian M. The role of dietary cholesterol in lipoprotein metabolism and related metabolic abnormalities: a mini-review. Crit Rev Food Sci Nutr. (2016) 56:2408–15. 10.1080/10408398.2013.842887 26055276 González-Aldaco K Torres-Reyes L Ojeda-Granados C José-Ábrego A Fierro N Román S. Immunometabolic effect of cholesterol in hepatitis c infection: implications in clinical management and antiviral therapy. Ann Hepatol. (2018) 17:908–19. 10.5604/01.3001.0012.7191 30600305 Erion D Park H Lee H. The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. BMB Rep. (2016) 49:139–48. 10.5483/bmbrep.2016.49.3.268 26728273 Yang H Wei Y Mao Q Zhao L. Immune activation induced by dysregulated lipid metabolism in the pathogenesis of type 2 diabetes. World J Diabetes. (2025) 16:114395. 10.4239/wjd.v16.i12.114395 41480598 Wang X Sun Z Liu Q Zhou Q Jiang G. Environmental obesogens and their perturbations in lipid metabolism. Environ Health. (2024) 2:253–68. 10.1021/envhealth.3c00202 39474325 Benito-Vicente A Uribe K Jebari S Galicia-Garcia U Ostolaza H Martin C. Familial hypercholesterolemia: the most frequent cholesterol metabolism disorder caused disease. Int J Mol Sci. (2018) 19:3426. 10.3390/ijms19113426 30388787 Janssen J. The pivotal role of the western diet, hyperinsulinemia, ectopic fat, and diacylglycerol-mediated insulin resistance in type 2 diabetes. Int J Mol Sci. (2025) 26:9191. 10.3390/ijms26189191 41009753 Gowda D Shekhar C Gowda S Chen Y Hui S. Crosstalk between lipids and non-alcoholic fatty liver disease. Livers. (2023) 3:687–708. 10.3390/livers3040045 Alkhouri N Dixon L Feldstein A. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol. (2009) 3:445–51. 10.1586/egh.09.32 19673631

Edited by: Philippe Gérard, Institut National de recherche pour l’agriculture, l’alimentation et l’environnement (INRAE), France

Reviewed by: Kristal Potter, Larkin University, United States

Kusumakshi Nayak, MAHE, India